



(11) Publication number: **0 466 222 A1**

(12) **EUROPEAN PATENT APPLICATION**

(21) Application number: **91201436.2**

(51) Int. Cl.⁵: **C07K 15/10, C12N 15/29,
C12N 5/10**

(22) Date of filing: **10.06.91**

(30) Priority: **11.06.90 US 535636**

(43) Date of publication of application:
15.01.92 Bulletin 92/03

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(71) Applicant: **DOWELANCO**
9002 Purdue Road
Indianapolis, Indiana 46268-3030(US)

(72) Inventor: **Walsh, Terence A.**
E. Old Pine Trail
Midland, Michigan 48640(US)
Inventor: **Hey, Timothy D.**
3215 Garland Street
Midland, Michigan 48640(US)
Inventor: **Morgan, Alice E. R.**
4610 Bristol Court
Midland, Michigan 48640(US)

(74) Representative: **Smulders, Theodorus A.H.J.,**
Ir. et al
Vereenigde Octrooibureaux Nieuwe Parklaan
107
NL-2587 BP 's-Gravenhage(NL)

(54) **Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using.**

(57) The present invention is directed to ribosome inactivating proteins. The proteins are characterized by being in a single chain proRIP inactive form that can be converted into an active form by cleavage with proteases.

EP 0 466 222 A1

Ribosome-inactivating proteins (RIPs) are plant proteins that are capable of catalytically inactivating eukaryotic ribosomes and are consequently extremely potent inhibitors of eukaryotic protein synthesis. RIPs have been divided into two classes: type 1 and type 2 RIPs (see Barbieri and Stirpe (1982), Cancer Surveys, 1:489-520). There is significant amino acid sequence homology between members of both type 1 and type 2 RIPs, and with the bacterial Shiga and Shiga-like toxins which also have the same mechanism of action (see Hovde *et al.* (1988), Proc. Natl. Acad. Sci. USA, 85:2568-2572).

Type 2 RIPs consist of two polypeptides: an RIP (or A-chain) which is covalently attached via a disulfide bond to a lectin-like protein (or B-chain) with an affinity for cell surface carbohydrates. The B-chain binds to the cell surface and facilitates subsequent cellular internalization of the RIP A-chain moiety, which results in rapid inactivation of protein synthesis and cell death. Type 2 RIPs are therefore extremely potent cytotoxins and animal poisons, the best studied example of which is ricin.

In contrast type 1 RIPs, characterized to date, consist of a single polypeptide chain equivalent in activity to that of A-chain RIPs but lacking a covalently attached B-chain. Consequently, they are scarcely toxic to intact cells but retain their extreme potency against cell-free protein translation systems. Typical concentrations that inhibit cell-free protein translation by 50 percent (IC_{50}) are 0.5 to 10 ng/ml (0.16 to 33 pM). Until the discoveries detailed hereinbelow, reported type 1 RIPs were a remarkably homogeneous class of basic proteins with Mr values of about 30,000. Type 1 RIPs are found in a great variety of dicot and monocot plants and they may be ubiquitous. They are often abundant proteins in seeds, roots or latex for example. Their *in vivo* function is unclear but it has been proposed that they may be antiviral agents (see Stevens *et al.* (1981), Experientia, 37:257-259) or antifungal agents (see Roberts and Seltrennikoff (1986), Bioscience Reports, 6:19-29).

To date, one article has discussed the presence of an inhibitor of animal cell-free protein synthesis in maize, as well as other cereal crops (see Coleman and Roberts (1982), Biochimica et Biophysica Acta, 696:239-244). The preparation of the maize inhibitor was via ammonium sulfate precipitation and phosphocellulose column chromatography. It is generally believed that the inhibitor isolated from maize was pure. The reported molecular weight of the inhibitor was 23 kiloDaltons (kD), with a reported IC_{50} of 50 to 100 ng/ml in an ascites cell-free protein synthesis assay.

Where the effect of RIPs on ribosomes has been examined, both type 1 and type 2 RIPs possess a unique and highly specific N-glycosidase activity which cleaves the glycosidic bond of adenine 4324 of the rat liver ribosomal 28S RNA (see Endo (1988), In: Immunotoxins, (ed.) Frankel).

Commercial interest in RIPs has primarily focused on their use in construction of therapeutic toxins targeted to specific cells such as tumor cells by attachment of a targeting polypeptide, most frequently a monoclonal antibody (see Immunotoxins (1988), *supra*). This mimics the binding functionality of the B-chain of type 2 RIPs but replaces their non-specific action with a highly selective ligand. Another recent potential use is in HIV therapy (see U.S. Patent 4,869,903 to Lifson *et al.*, (Genelabs Incorporated and The Regents of the University of California)).

However, while a maize-derived protein synthesis inhibitor, like protein synthesis inhibitors from other *Panicoideae* would appear to be useful for construction of cytotoxic conjugates, no artisan to date has reported to have successfully used a *Panicoideae* RIP. This is somewhat surprising in view of the success achieved with RIPs from non-*Panicoideae* plants, including cereals such as barley (see Lambert *et al.* - (1988), In: Immunotoxins, *supra*). In part, the lack of success to date by skilled artisans in successfully utilizing the maize RIP described by Coleman and Roberts may be attributed to the fact that the protein synthesis inhibitor was relatively uncharacterized.

There is interest in expressing recombinant RIP in commonly employed host eukaryotic cells, because of the capacity to provide correct post-translational processing. However, as RIPs effectively inhibit protein synthesis in eukaryotic cells, a predictable problem is that heterologous expression of an RIP will result in host cell death. Thus, eukaryotic cells are generally not used as recombinant host cells. Although eukaryotic cells may be used in certain circumstances, the RIP must be constructed so as to be secreted prior to the cell experiencing toxicity (see EP 0 335 476 to Gelfand *et al.* (Cetus Corp.)). Therefore, prokaryotic host cells are generally used as hosts, notwithstanding disadvantages such as the inability to glycosylate and properly fold heterologously expressed proteins.

It is thus an object of the invention to provide a method of preparing inactive forms of RIPs, in which an inactive RIP may be expressed by eukaryotic host cells and then converted to an active form.

It is yet another object of the invention to provide the DNA sequence of the gene encoding at least one inactive form of RIP, as well as expression vehicles, host cells and cell cultures containing such DNA sequence.

Other objects and advantages of the present invention will become apparent from the teachings presented hereinafter.

It is to these objects to which the present invention is directed.

In a first aspect, the present invention is directed to a homogeneous protein, termed a proRIP, wherein the protein is incapable of substantially inactivating eukaryotic ribosomes, but which can be converted into a protein, termed an $\alpha\beta$ RIP, that is capable of substantially inactivating eukaryotic ribosomes, said proRIP having a removable, internal peptide linker sequence.

In a second aspect, the present invention is directed to a homogeneous protein derived from *Panicoideae*, termed a proRIP, wherein the proRIP has a removable, internal peptide linker sequence and is incapable of substantially inactivating eukaryotic ribosomes, but which upon removal of the linker can be converted into a protein having α and β fragments, termed an $\alpha\beta$ RIP, that is capable of substantially inactivating eukaryotic ribosomes.

In a third aspect, the present invention is directed to a homogeneous protein derived from *Panicoideae*, termed an $\alpha\beta$ RIP, that is capable of substantially inactivating eukaryotic ribosomes, wherein the RIP has α and β fragments.

In a fourth aspect, the present invention is directed to a homogeneous protein derived from maize, termed a proRIP, wherein the proRIP has a removable, internal peptide linker sequence and is incapable of substantially inactivating eukaryotic ribosomes, but which upon removal of the linker can be converted into a protein having α and β fragments, termed an $\alpha\beta$ RIP, that is capable of substantially inactivating eukaryotic ribosomes, said α fragment having an amino acid sequence effectively homologous to the following sequence:

KRIVPKFTEIFPVEDANYPYSAFIASVRKDKVIKHCTDHKGIFQPVLPPEKKVPELW
FYTELKTRTSSITLAIRMDNLYLVGFRTPGGVWWEFGKD
GDTHLLGDNPRWLGFGGRYQDLIGNKGLETVTMGRAEMTR
AVNDLAKKKK

and said β fragment having an amino acid sequence effectively homologous to the following sequence:

DPQADTKSKLVKLVVMVCEGLRFNTVSRTVDAGFNSQHGVTLLVTQGKQVQKWDR
SKAAFEWADHPTAVIPDMQKLGKDKNEAARIVAL
VKNQTTAAATAASADNDDEA.

In a fifth aspect, the present invention is directed to a method of converting a protein that is incapable of substantially inactivating eukaryotic ribosomes into a protein that is capable of substantially inactivating eukaryotic ribosomes, said method comprising the following steps:

- a) providing a homogeneous protein derived from *Panicoideae*, termed a proRIP, wherein the proRIP has a removable, internal peptide linker sequence and is incapable of substantially inactivating eukaryotic ribosomes, but which upon removal of the linker can be converted into a protein having α and β fragments, termed an $\alpha\beta$ RIP, that is capable of substantially inactivating eukaryotic ribosomes; and
- b) contacting the proRIP with a cleaving agent capable of deleting the linker to form a protein having α and β fragments, termed an $\alpha\beta$ RIP, that is capable of substantially inactivating eukaryotic ribosomes.

In a sixth aspect, the present invention is directed to a conjugate comprising a targeting vehicle and a protein derived from *Panicoideae*, termed a proRIP, wherein the proRIP has a removable, internal peptide linker sequence and is incapable of substantially inactivating eukaryotic ribosomes, but which upon removal of the linker can be converted into a protein having α and β fragments, termed an $\alpha\beta$ RIP, that is capable of substantially inactivating eukaryotic ribosomes.

In a seventh aspect, the present invention is directed to a conjugate comprising a targeting vehicle and a protein derived from *Panicoideae*, termed an $\alpha\beta$ RIP, that is capable of substantially inactivating eukaryotic ribosomes, wherein the $\alpha\beta$ RIP has α and β fragments.

In an eighth aspect, the present invention is directed to a conjugate comprising a targeting vehicle and a protein derived from maize, termed a proRIP, wherein the proRIP has a removable, internal peptide linker sequence and is incapable of substantially inactivating eukaryotic ribosomes, but which upon removal of the linker can be converted into a protein having α and β fragments, termed an $\alpha\beta$ RIP, that is capable of substantially inactivating eukaryotic ribosomes, said α fragment having an amino acid sequence effectively homologous to the following sequence:

KRIVPKFTEIFPVEDANYPYSAFIASVRKDVIKHCTDHKGIFQPVLPPEKKVPELW
 FYTELKTRTSSITLAIRMDNLYLVGFRTPGGVWWEFGKD
 5 GDTHLLGDNPRWLGFGGRYQDLIGNKGLETVTMGRAEMTR
 AVNDLAKKKK

and the β fragment having an amino acid sequence effectively homologous to the following sequence:

10 DPQADTKSKLVKLVVMVCEGLRFNTVSRTVDAGFNSQHGVTLLTVTQGKQVQKWDR I
 SKAAFEWADHPTAVIPDMQKLGIKDKNEAARIVAL
 15 VKNQTTAAAATAASADNDDDEA.

In a ninth aspect, the present invention is directed to a DNA isolate capable of encoding a protein, termed a proRIP, wherein the proRIP has a removable, internal peptide linker sequence and is incapable of substantially inactivating eukaryotic ribosomes, but which upon removal of the linker can be converted into a protein having α and β fragments, termed an $\alpha\beta$ RIP, that is capable of substantially inactivating eukaryotic ribosomes.

In a tenth aspect, the present invention is directed to a DNA isolate encoding a protein, termed an $\alpha\beta$ RIP, that is capable of substantially inactivating eukaryotic ribosomes, wherein the $\alpha\beta$ RIP has α and β fragments.

25 In an eleventh aspect, the present invention is directed to a DNA isolate encoding a protein derived from maize, termed a proRIP, wherein the proRIP has a removable, internal peptide linker sequence and is incapable of substantially inactivating eukaryotic ribosomes, but which upon removal of the linker can be converted into a protein having α and β fragments, termed an $\alpha\beta$ RIP, that is capable of substantially inactivating eukaryotic ribosomes, said α fragment having an amino acid sequence effectively homologous
 30 to the following sequence:

KRIVPKFTEIFPVEDANYPYSAFIASVRKDVIKHCTDHKGIFQPVLPPEKKVPELW
 35 FYTELKTRTSSITLAIRMDNLYLVGFRTPGGVWWEFGKD
 GDTHLLGDNPRWLGFGGRYQDLIGNKGLETVTMGRAEMTR
 AVNDLAKKKK

40 and said β fragment having an amino acid sequence effectively homologous to the following sequence:

45 DPQADTKSKLVKLVVMVCEGLRFNTVSRTVDAGFNSQHGVTLLTVTQGKQVQKWDR I
 SKAAFEWADHPTAVIPDMQKLGIKDKNEAARIVAL
 VKNQTTAAAATAASADNDDDEA.

In a twelfth aspect, the present invention is directed to a DNA isolate encoding a fusion protein capable of substantially inactivating eukaryotic ribosomes, said protein having an amino acid sequence effectively
 50 homologous to the following sequence:

KRIVPKFTEIFPVEDANYPYSAFIASVRKDVIKHCTDHKGIFQPVLPPPEKKVPELW
 FYTELKTRTSSITLAIRMDNLYLVGFRTPGGVWWEFGKD
 GDTHLLGDNPRWLGFGGRYQDLIGNKGLETVTMGRAEMTR
 5 AVNDLAKKKKDPQADTKSKLVKLVVMVCEGLRFNTVSRTVDAGFNSQHG
 VTLT VTQ GKQVQKWDRISKAAFEWADHPTAVIPDMQKLGIKDKN
 EAARIVALVKNQTTAAAATAASADNDDDEA.

10 In other aspects, the invention is directed to expression vehicles capable of effecting the production of such aforementioned proteins in suitable host cells. It also includes the host cells and cell cultures which result from transformation with these expression vehicles.

A number of aspects of the present invention are further illustrated in the accompanying Drawings, in
 15 which:

Figure 1 shows a schematic representation of the processing of maize proRIP to the active form.

Figure 2 shows the effect of active maize $\alpha\beta$ RIP on mammalian cell-free protein synthesis.

The entire teachings of all references cited herein are incorporated by reference.

20 Definitions

Nucleic acids, amino acids, peptides, protective groups, active groups and so on, when abbreviated, are abbreviated according to the IUPACIUB (Commission on Biological Nomenclature) or the practice in the fields concerned. The following are examples.

25 The single letter code for amino acids is set forth below:

Glycine:	G	Phenylalanine:	F
Alanine:	A	Tyrosine:	Y
Valine:	V	Threonine:	T
30 Leucine:	L	Cysteine:	C
Isoleucine:	I	Methionine:	M
Serine:	S	Glutamic acid:	E
Aspartic acid:	D	Tryptophan:	W
35 Lysine:	K	Proline:	P
Arginine:	R	Asparagine:	N
Histidine:	H	Glutamine:	Q
Unknown	X		

40 The term "proRIP" means a precursor protein that contains a leader and linker and that is not capable of inactivating eukaryotic ribosomes.

The term "leader" refers to an N-terminal amino acid sequence of a proRIP that need not present in the mature, fully active form of the $\alpha\beta$ RIP.

The term "linker" refers to an internal amino acid sequence within a proRIP, whereby the linker is of a
 45 length and contains residues effective to render the proRIP incapable of catalytically inhibiting translation of a eukaryotic ribosome.

The term "RIP" means a protein that is capable of inactivating eukaryotic ribosomes. The term " $\alpha\beta$ RIP" means a RIP having an α fragment, which may or may not contain the leader, a β fragment and being capable of substantially inactivating eukaryotic ribosomes.

50 The term "IC₅₀" means the concentration of a protein necessary to inhibit protein synthesis by 50 percent in a cell-free protein synthesis assay.

The term "inhibiting amount" refers to the specific ability of RIPs to cause the death or injury of cells against which they are targeted.

The term "target cells" means those cells having ribosomes which the $\alpha\beta$ RIP of the present invention
 55 is capable of inhibiting. The target cells may be present in living organisms or they may be preserved or maintained *in vitro*. The cells may be individual or associated to form an organ. Exemplary target cells include any eukaryotic cell (e.g., mammalian, insect, fungal and plant cells).

The term "targeting vehicle" means a carrier moiety containing a ligand capable of binding to a

receptor of a specific cell or tissue.

"Gene" refers to the entire DNA portion involved in the synthesis of a protein. A gene embodies the structural or coding portion which begins at the 5' end from a translation start codon and extends to a stop codon at the 3' end. It also contains a promoter region, usually located 5' or upstream to the structural coding portion, which initiates and regulates the expression of a structural gene and a 3' nontranslated region downstream from the translated region.

"Expression" refers to a two-part process for the transcription and translation of a gene. The DNA defining the gene is transcribed into a precursor RNA, which is processed to its mature form, messenger RNA (mRNA). During translation, the cell's ribosomes, in conjunction with transfer RNA, translate the RNA "message" into proteins.

Preferred Embodiments of the Invention

Surprisingly, it has been discovered that studied members of *Panicoideae* contain $\alpha\beta$ RIP and proRIP. *Panicoideae* is a subfamily of *Gramineae* (order) and *Graminaceae* (family). The subfamily *Panicoideae* contains three tribes: *Maydeae* (e.g., *Tripsacum*, *Coix*, *Euchlaena* and *Zea*), *Andropogoneae* (e.g., *Sorghum*) and *Paniceae*. For further taxonomic information, see Arber (1934), The Gramineae, A Study of Cereal, Bamboo and Grass, Cambridge University Press, p 410-411.

The present invention pertains to proteins which are derived from a plant within the subfamily *Panicoideae*. As taught herein, proteins obtained from various plants within the subfamily *Panicoideae* have shown antigenic cross reactivity (i.e., showing evidence of proRIP in *Panicoideae* as well as α and β fragments of an $\alpha\beta$ RIP).

By "derived" from a plant within the subfamily *Panicoideae* means a protein that is effectively homologous, as defined below, with a proRIP or $\alpha\beta$ RIP from *Panicoideae*, regardless of the manner in which the protein is produced. Given the present teachings it now becomes possible to prepare generally homogeneous proRIP and $\alpha\beta$ RIP exclusive of irrelevant proteins and contaminants naturally associated therewith in the cellular environment or in extracellular fluids. For example, a substantially pure protein will show constant and reproducible characteristics within standard experimental deviations for parameters such as the following: molecular weight, chromatographic behavior, and such other parameters. The term, however, is not meant to exclude artificial or synthetic mixtures of a protein with other compounds. The term is not meant to exclude the presence of minor impurities which do not interfere with the biological activity of the protein and which may be present, for example, due to incomplete purification.

Both the proRIP and $\alpha\beta$ RIP may be purified directly from mature and germinating seeds and developing kernels of plants within the subfamily. Generally, the purification of the *Panicoideae* $\alpha\beta$ RIP and proRIP may be accomplished as follows.

Seeds or immature kernels of plants within the subfamily *Panicoideae* may be homogenized to disrupt the individual seeds or kernels. This can be accomplished by any type of commercially available homogenizer.

The *Panicoideae* proRIP and/or $\alpha\beta$ RIP may be purified from the homogenization product by any appropriate protein purification technique. Exemplary techniques include gel filtration chromatographic techniques, such as conventional liquid chromatography, ion exchange chromatography, high performance liquid chromatography, and reverse phase chromatography.

Upon purification, the *Panicoideae* proRIP will have insignificant ribosome inactivating ability relative to its corresponding $\alpha\beta$ RIP. For example, maize proRIP has an IC_{50} of greater than 10 micrograms per milliliter ($\mu\text{g/ml}$) in a cell-free protein synthesis assay. The maize $\alpha\beta$ RIP has an IC_{50} of about 1 nanogram per milliliter (ng/ml) in a mammalian cell-free protein translation assay.

The maize proRIP has a molecular weight of about 34 kD, as determined by SDS-PAGE (see Laemmli (1970), *supra*), and will move as a single peak on ion exchange chromatography. Homogeneous maize $\alpha\beta$ RIP will comprise two associated fragments, an α and β fragment, having molecular weights of approximately 16.5 kD and 8.5 kD, respectively (as determined by sodium dodecyl sulfate polyacrylamide-gel electrophoresis (SDS-PAGE) (see Laemmli ((1970), *Nature*, 22:680-685). The homogeneous protein will exhibit two dissociated peaks on reverse phase chromatography, and a single associated peak on ion exchange chromatography. Polyclonal anti-sera against each fragment both crossreact with a polypeptide present in maize kernels having a molecular weight of about 34 kD as determined by SDS-PAGE. This demonstrates that the two fragments of the maize $\alpha\beta$ RIP are in fact derived from a common precursor (i.e., the maize proRIP).

The maize proRIP amino acid sequence (as set forth in Table 1) contains four sequence subsegments: (1) a leader sequence, from residues 1 to 16, (2) an α fragment, from residues 17 to 156, (3) an internal

linker sequence, from residues 157 to 182, and (4) $\alpha\beta$ fragment, from residues 183 to 301.

TABLE 1

Nucleotide sequence and deduced amino acid sequence of maize proRIP cDNA.

5	1	GAA TTC GGC ACC ACC AAA GAG AAG GGA ATG GCG GAG ATA ACC GTA GAG CGG
		Met Ala Glu Ile Thr Leu Glu Pro
10	32	AGT GAT GTT ATG GCG CAA ACA AAC AAA AGA ATA GTG CCA AAG TTC ACT GAA
		Ser Asp Leu Met Ala Gln Thr Asn Lys Arg Ile Val Pro Lys Pro Thr Glu
	103	ATC TTC GCG GTG GAG GAC GCG AAC TAC CCG TAC AGC GCG TTC ATC GCG TCG
	106	Ile Phe Pro Val Glu Asp Ala Asn Tyr Pro Cys Ser Ala Phe Ile Ala Ser
15	154	GTG GCG AAA GAC GTG ATC AAA CAC TCG ACC GAC CAT AAA GCG ATC TTC CAG
	157	Val Arg Lys Asp Val Ile Lys His Cys Thr Asp His Lys Gly Ile Phe Gln
	205	GCG GTG GTG CCA GCG GAG AAG AAG GTC GCG GAG GTA TGG TTC TAC ACA GAG
	208	Pro Val Leu Pro Pro Glu Lys Lys Val Pro Glu Leu Trp Phe Tyr Thr Glu
20	256	GTG AAA ACT AGG ACC ACC TCG ATC ACG CTC GCG ATA CGC ATG GAC AAC CTC
	259	Leu Lys Thr Arg Thr Ser Ser Ile Thr Leu Ala Ile Arg Met Asp Asn Leu
	307	TAC CTC CTC GCG TTC AGG ACC GCG GCG GCG GTC TCG TCG GAG TTC GCG AAG
	310	Tyr Leu Val Gly Phe Arg Thr Pro Gly Gly Val Trp Trp Glu Phe Gly Lys
25	358	GAC GCG GAC ACC GAC CTC CTC GCG GAC AAC GCG AGG TCG CTC GCG TTC GCG
	361	Asp Gly Asp Thr Ala Leu Leu Gly Asp Asn Pro Arg Trp Leu Gly Phe Gly
	409	GCG AGG TAC CAG GAC CTC ATC GCG AAC AAG GGT CTC GAG ACC CTC ACC ATG
	412	Gly Arg Tyr Gln Asp Leu Ile Gly Asn Lys Gly Leu Glu Thr Val Thr Met
	460	GCG GCG GCG GAA ATG ACC AGG GCG CTC AAC GAC CTC GCG AAG AAG AAG AAG
	463	Gly Arg Ala Glu Met Thr Arg Ala Val Asn Asp Leu Ala Lys Lys Lys Lys
30	511	ATG GCG ACA CTC GAG GAG GAG GAG CTC AAG ATC CAG ATC CAG ATC GCG GAG
	514	Met Ala Thr Leu Glu Glu Glu Glu Val Lys Met Gln Met Gln Met Pro Glu
	562	GCG GGT CAT CTC GCG GCG GCG GCG GCA GCG GGT GAC CCA CAG GCG GAC ACC AAG
	565	Ala Ala Asp Leu Ala Ala Ala Ala Ala Asp Pro Gln Ala Asp Thr Lys
35	613	AGC AAG CTC CTC AAG CTC CTC CTC ATC CTC TCG GAG GCG CTC GCG TTC AAC
	616	Ser Lys Leu Val Lys Leu Val Val Met Val Cys Glu Gly Leu Arg Phe Phe
	664	ACC CTC TCG GCG ACC CTC GAC GCG GCG CTC AAC ACC CAG GAC GCG CTC ACC
	667	Thr Val Ser Arg Thr Val Asp Ala Gly Phe Asn Ser Gln His Gly Val Thr
40	715	TTC ACC CTC ACC CAG GCG AAG CAG CTC CAG AAG TCG GAC ACC ATC TTC AAG
	718	Leu Thr Val Thr Gln Gly Lys Gln Val Ala Lys Trp Asp Arg Val Ser Lys
	766	GCG GCG TTC CAG TCG GGT CAG CAG GCG ACC GGT CTC ATC GCG CAG ATC CAG
	769	Ala Ala Phe Glu Thr Ala Asp His Pro Thr Ala Val Ile Pro Asp Met Gln
45	817	AAG GGT GCG ATC AAG CAT AAG AAC GAA GCA GCG AGG ATC GGT GCG GGT GGT
	820	Lys Leu Gly Ile Lys Asp His Asn Thr Val Ala Arg Ile Val Ala Val Val
	868	AAG AAT GAA ACT GGT GCG GGT TCG GGT ACT GGT GCG AGT GGT CAG AAC CAG
	871	Lys Asn Gln Thr Thr Ala Ala Ala Ala Thr Ala Ala Ser Ala Asp Asn Asp
	919	TAC GAG GAG GCG TGA TGA ATG GAA GCA GAG ATC ATG ATC TCG TCG TCG ACT
	922	Asp Asp Glu Ala Ser
50	970	TAA TTA CCA TGT TCG CAT ACA CAT AAA TAC ACC GCG GGT TCG GCG TGT TCG
	973	Stop Stop Ser Stop Phe Stop Stop Stop TAC ACC CAG TGT TTC GCG GCG
	1021	TAA TAT GCG CTA AAA GGT ACC GAG TAA ATT TCA AAC CAG TGT TTC GCG GCG
	1072	AAT TC

The net charges of these polypeptides are as follows: leader -3; α , +10; linker, -5; β , +1. Removal of the leader and linker results in a dramatic change in net charge from the maize proRIP (+3) to maize $\alpha\beta$ RIP (+11). Additionally, the proRIP isolated from maize has an observed pI of 6.5 which agrees well with

5 consistent with the pI of other RIPs.

TABLE 2

Comparison of maize RIP and barley RIP amino acid sequences.

```

20      -----AAKMAKNVDKPLFTATFENVQASSADYATFIAGIRNKLRNPA--HFSHNEFPV
61     LFF-EKKVPPEL-WFYTELKER-TSS-ITLAIRMONLYLVGFRTPGGVWWEFGKGGDTHLLG
80     LPFVEPNVPPSRWFHVVLKASPTSEAGLTALRADNIYLEGFKSSDGTWWELT7GLIPGAT-
25    119   INPRWLGGGGRYQDLIGNKGLET-VTMGRAEMTRAVNDLAKKKKMATLEEEEVKMMOMPE
        :!!!!          :
    110   ----LVGGGGTYRDLIGDTCKLTVVALGRQOLEDVA TALHGRTX-----
197   AADZAAAAAADPQADTKSKLYKLVMVCEGLRENTVSRTVDAGFNSOHGVTLT----VTQG
30    180   ----ADKASGFKQQQAREAVTTLLLMVNEATRFOQTYSGEVAGLLHPKAVEPKSGKIGNEMK
        :!!!!          :
    186   KQVCKWDRI SKAAF EWADHTAVIFDMCKLGIKDKNEAARIVALVKNOTTAAAATAASADN
        :!!!!          :
35    187   AQVNGWQDLIS-AALLX----TDVKPPPCKSPAKFTPIEKMGVRTAEQ-----AATLGILLF
        :!!!!          :
    187   DDEEA
        :!!!!          :
    189   NEVFEGLTWAKALELFHASGGK

```

45 proRIP sequence is compared to that of ricin A-chain (as set forth in Table 3 below). The upper sequence is maize $\alpha\beta$ RIP and the lower sequence is ricin A, as taught by Lamb *et al.* (1985), *Eur. J. Biochem.*, **148**:265. Identical residues are denoted by a solid line and conservative substitutions by a dotted line, dashes indicate insertions to maximize homology. Residues are numbered on the left, the numbering of the ricin sequence corresponds to that of the mature protein.

TABLE 3

Comparison of maize RIP and ricin A chain amino acid sequence.

5

	1	-----MAEITLEPSDLMAQTNKRIVPKFTEIFPVEDANYPYSAFIASVRKDVIKHCT
		: : :
-24		MYAVATWLCFGSTSGWSFTLEDNNIFPKQYPIINFTTAGATVQSYTNFIRAVRGRLTTGAD
10		
62		DHKGIFQPVLPPEKKVPELWF-YTELKTR-TSSITLAIRMDONLYLVGFRTPGGVWWEFGK
		: : : : : : :
38		VR--HEIPVLPNRVGLPINQRFILVELSNHAELSVTLALDVTNAYVVGYRAGNSAYFFHPD
110		DGDTHLLGDNPR-----WLGFGGGRYQDLIGNKGL--ETVTMGRAEMTRAVNDLAKKKKM
		: : : :
97		NQEDAEAIHFLFTDVQNRITFAFGGNYDRLEQLAGNLRENIELGNPLEEAISSALYYTST-
164		ATLEEEEVQMOMQOMPEAADLAAAAAADPQADTKSKLVKLVVMVCEGLRFNTVSRTVDAGFN
		: : : :
20	157	-----GGTQLPTLARSFIICIQMISEAARFQYIEGEMRTRIR
224		SOHGVTLTQTGGKQVQKWDRIKAAFEWADHPTAVIPDMQKLGK-KDKNEAARIVALVKNQ
		: : : : : :
194		YNRRSAPDPSPVITLLENSWGLSTAIQESNQGAFAPIQLQRRNGSKFSVYDVSILIPIAL
25	284	TTAAAATAASADNDDEA
255		MVYRCAPPPSQF

30 As set forth in Table 3, a gap was again introduced in the published ricin A sequence to maximize homology corresponding to the linker region of the maize proRIP.

Further comparison of the maize proRIP sequence with published full-length sequences of other non-*Panicoideae* RIPs indicate that there are four regions of significant homology between these proteins (as set forth in Tables 4a and 4b below).

35

TABLE 4A

40 Alignment of the N-terminal amino acid sequence of the maize RIP 16.5 kD polypeptide with the N-termini of RIPs from other sources.

45	Maize RIP	AQTNKRIVPKFTEIF-PVEDANYPYSAFIASVRKDVIK
	Barley RIP	AAKMAKNVDKPLFTATF-NVQASSADYATFIAGIRNKLRLN
	Ricin A	IFPKQYPIINFTTAGATVQSYTNFIRAVRGRLTT
	Trichosanthin	DVSFRLSGATSSSYGVFISNLRKALPN
	Momordin	DVSFRLSGADPRSYGMFIKDLRNALPF
50	Bryodin	DVSFRLSGATTTSYGVFIKNLREALPY
	Gelonin	GLDTVSFSTKGATYITYVNFELNELRVKLKP
	Dodecantrin	VNTIIYNVGSTTISNYATFMDNLRNEAKD
	Pokeweed AP2	N-IVFDYENATPETYSNFLTSLREAVKD
	Saporin 5	VTSTLTLVNPTAGQYSSFDKIPNNVKD
55	Saporin 4	VIIIEELNLQGTTKAQYSTILKQLRDDIKD
	SLT-1A	KEFTLDFSTAKTYDSLNV-IRSAIGT

Table 4A shows the first region and the comparative alignment of the N-terminal amino acid sequence of the maize $\alpha\beta$ RIP α fragment with the N-terminal sequences of RIPs from other sources. The sequences are taken from: barley (see Asano *et al.* (1986), *supra*); ricin A-chain (see Lamb *et al.* (1985), *supra*); dodecandrin (see Ready *et al.* (1985), *Biochem. Biophys. Acta*, 791:314); pokeweed anti-viral protein 2 (AP2) (see Bjorn *et al.* (1985), *Biochim. Biophys. Acta*, 790:154); Shiga-like toxin 1A (SLT-1A) (see Calderwood *et al.* (1987), *Proc. Nat. Acad. Sci. USA*, 84:4364); and α -trichosanthin, momordins, bryodin, gelonin, dodeoandrin, pokeweed antiviral protein-2, saporin 5, and saporin 4 (see Montecucchi *et al.* (1989), *Int. J. Peptide Res.*, 33:263). Positions showing homology in four or more sequences are noted by solid lines (showing identical residues) or dotted lines (showing conservatively substituted residues).

TABLE 4B

Alignment of maize RIP with regions of homology in the amino acid sequences of other RIPs.

Maize RIP	84	<u>ITLAIRMDNLYLVGE</u>	201	<u>LVVMVCEGLRENTYS</u>	237	<u>QVOK-HDRISKA</u>
Barley RIP	77	<u>LTLAIRADNLYLVGE</u>	168	<u>LLLMVNEATREOTYS</u>	208	<u>QVNG-HODLSAA</u>
Ricin A-chain	70	<u>VTLLALDVTNAXVVG</u>	171	<u>CIOMISEAARFOYIE</u>	207	<u>LENS-HGRISTA</u>
Saporin-6	62	<u>VSLGLKRONLYVWAY</u>	170	<u>AIOMTAEAAERFYIQ</u>	205	<u>EYN-HKKISTA</u>
Abrin A-chain	64	<u>LEVGLDVTNAXVWAY</u>	159	<u>LIQVASEAARERYIS</u>	194	<u>LENN-HDNLRGV</u>
SLT-1A	62	<u>MIDSGSGDNLEAVDV</u>	183	<u>FYTVTAELRFOIQR</u>	222	<u>TLN-HGRILSSV</u>
Trichosanthin	58	<u>DEVALDVTNY...</u>	161	<u>LIQSTSEAAARYKFIE</u>	195	<u>LENSLNLALSKQ</u>
	77	<u>LMGY</u>				

Table 4b shows that the other three regions are internally oriented. Table 4b specifically shows the alignment of maize $\alpha\beta$ RIP with regions of homology in the amino acid sequences of other RIPs. The sequences are available from the following references: barley (see Asano *et al.* (1986), *supra* and Leah *et al.* (1991), *J. Biol. Chem.*, 266:1564-1573); ricin A-chain (see Lamb *et al.* (1985), *supra*); abrin A-chain (see Funatsu *et al.* (1988), *Agric. Biol. Chem.* 52:1095); saporin-6 (see Benatti *et al.* (1989) *Eur. J. Biochem.*, 183:465); Shiga-like toxin 1A (SLT-1A) (see Calderwood *et al.* (1987), *supra*); and α -trichosanthin (see Xuejun and Jiahuai (1986), *Nature*, 321:477; Chow *et al.* (1990), *J. Biol. Chem.*, 265:8670-8674 and Maragonore *et al.* (1987), *J. Biol. Chem.*, 262:11628-11633). Positions showing identity or conservative substitutions in four or more sequences are underlined, dashes indicate insertions to maximize homology. Vertical lines indicate residues that are conserved in all seven sequences. The starting amino acid of each sequence is indicated (note that trichosanthin contains an insertion sequence at residues 67 to 76).

The sequences and partial sequences of various additional Type I RIPs are set forth in the following articles: luffin-A (see Islam *et al.* (1990), *Agric. Biol. Chem.*, 54:2967-2978; mirabilis antiviral protein (see Habuka *et al.* (1989) *J. Bio. Chem.*, 264:6629-6637; trichokirin, (see Casellas *et al.* (1988), *Eur. J. Biochem.*, 176:581-588; momordins (see Barbieri *et al.* (1980), *Biochem. J.*, 186:443-452; dianthins (see Reisbig and Bruland (1983), *Arch. Biochem. Biophys.*, 224:700-706; saporins (see Maras *et al.* (1990), *Biochem. Intl.*, 21:831-838 and Lappi *et al.* (1985), *Biochem. Biophys. Res Commun.*, 129:934-942; and momorcochin-S (see Bolognesi *et al.* (1989), *Biochim. Biophys. Acta*, 993:287-292).

Other Type I and Type II RIPs have also been purified to homogeneity and these include; momorcharins (see Yeung *et al.* (1986), *Int. J. Peptide Res.*, 28:518-524; tritins (see Roberts and Stewart (1979), *Biochem.*, 18:2615-2621); rye (see Coleman and Roberts (1982), *Biochim. Biophys. Acta*, 696:239-244; agrostins and *Hura crepitans* (see Stirpe *et al.* (1983), *Biochem. J.*, 216:617-625; *Asparagus officinalis* - (see Stirpe *et al.* (1983), *Biochem. J.*, 216:617-625; *Cucumis melo* (see Ferreras *et al.* (1989), *Biochem Intl.*, 19:201-207; *Cucurbitaceae* (see Ng *et al.*, *Int. J. Biochem.*, 21:1353-1358; *Petrocoptis* (see Ferreras *et al.*, *Cell. Molec. Biol.*, 35:89-95); volkensin-a (see Barbieri *et al.* (1984), *FEBS Lett.*, 171:277-279; viscumin-a (see Olsnes *et al.* (1982), *J. Biol. Chem.*, 257:13263-13270; modeccin-a (see Gasperi-Campani (1978), *Biochem. J.*, 174:491-496); *Momordia charantia* lectin-a (see Lin *et al.* (1978), *Linn. Toxicon.*, 16:653-660); *Phorandendron californicum* lectin-a (see Franz *et al.* (1989), *FEBS Lett.*, 248:115-118).

Proteins from the following other plants have also been shown to possess ribosome inactivating activity:

Stellarea holostea, *Lychnis flos-cuculi*, *Hordeum murinum*, *Aegilops geniculata*, *Euphorbia serrata*, *Capsella bursapastoris*, *Muscari comosum* (see Merino *et al.* (1990), *J. Exp. Botany*, **41**:67-70); and proteins from *Croton tiglium* and *Jatropha curcas* (see Stirpe *et al.* (1976), *Biochem J.*, **156**:1-6).

When the internal linker sequence of the proRIP is removed, the $\alpha\beta$ RIP has significant ribosome inactivating activity. The activity has been found to be significant regardless of whether the leader sequence has been removed (e.g., by recombinant methods). However, the proRIP is most active when the leader sequence is also removed and probably when C-terminus residues are also removed. In nature, it is thought that the linker is cleaved by endogenous proteases released by germinating seeds. Significantly, it has been discovered that the linker may also be cleaved *in vitro* by certain proteases, e.g., papain, to yield active maize $\alpha\beta$ RIP from the precursor. While not intended to be bound by theory, it is thought that papain likely mimics the effect of endogenous endoproteinases released during germination.

It appears that, after removal of the internal linker, the two fragments of the processed polypeptide are held together by noncovalent forces. That is, the association of the two polypeptide chains does not depend upon interchain disulfide bonds or the formation of a peptide bond between the fragments.

Although not intended to be bound by theory, it is believed that the linker forms an external loop with exposed amino acid residues that are susceptible to proteolysis. Support for this suggestion comes from the alignment of the amino acid sequence of the maize proRIP with that of ricin A chain, the three dimensional structure of which is known (see Montfort *et al.* (1987), *J. Biol. Chem.*, **262**:5398). The Glu 177, Arg 180, Asn 209 and Trp 211 of ricin A have been implicated in the active site region of the molecule (see Robertus (1988), *In: Immunotoxins, supra*).

Based on this alignment, homologous residues of maize $\alpha\beta$ RIP can be positioned within the three dimensional structure of ricin A chain. The superimposed structures indicate that the C-terminal lysine of the α fragment (at residue 162) is in corresponding alignment with an externally positioned threonine (at residue 156) of the ricin A-chain. Also, the N-terminal alanine of the β fragment (at residue 189) is in corresponding alignment with an externally positioned glycine (at residue 157) of the ricin A-chain.

The present invention is intended to include the construction of $\alpha\beta$ RIP and proRIP forms of any RIP. As set forth in Tables 4a and 4b, RIPs for which a full-length sequence has been determined contain regions with significant homology. Similarly the N-terminal sequence similarities in an even greater number of RIPs have been compared (set forth in Tables 4a and 4b). It is likely that these regions have particular effect upon the function of the respective RIP.

An RIP having known amino acid sequences may now be altered into inactive, proRIP forms by the insertion of a linker. Based on the information deduced from the maize system set forth herein, it now becomes possible to engineer inactive forms of any RIP having a three dimensional structure similar to the three dimensional structure of ricin A chain. Cleavage of the linker will result in an $\alpha\beta$ RIP not heretofore found in nature.

The art has discussed the methodology for modifying the three dimensional structure of proteins (see, for example, Van Brunt (1986), *Biotechnology*, **4**:277-283). The first step involves selecting plausible sites on the RIP between which the linker may be inserted. One of those sites is the exposed amino acid residues surrounding residue 156 of ricin A-chain or its equivalent in other RIP sequences. Thus, the present invention is intended to encompass the insertion of a peptide linker in those sequences, provided that the insertion of the linker substantially reduces the ribosome inactivating ability of the RIP. By "substantially reduce" is meant that the insertion of a cleavable linker into an active RIP lowers the IC_{50} value of the resultant protein by at least 10 fold, preferably 100-fold, and more preferably 1000-fold.

As stated previously, ricin A-chain has been shown to have sequence homology to many single chain RIPs. The RIPs set forth in Tables 4a and 4b are intended for exemplification purposes only. RIPs characterized in the future that meet the above criteria are also considered to be a part of this invention.

Generally, the linker may be of a length, may be of an amino acid sequence, and may be internally positioned so as to substantially reduce the ribosome inactivating activity of the RIP.

Obviously, since the *Panicoideae* linker(s) is the only known RIP linker found in nature, it is expected that such an amino acid sequence will logically be a primary candidate for insertion into other RIPs. However the present invention is intended to encompass linkers having effectively homologous sequences to a selected maize linker. The factors to be considered in synthetically preparing effectively homologous linkers for $\alpha\beta$ RIPs generally are the same as set forth above for selecting effectively homologous linkers for a selected maize linker.

Any of a variety of procedures may be used to clone proRIP-encoding gene sequence. One method for cloning the proRIP gene sequence entails determining the amino acid sequence of the proRIP molecule. To accomplish this task proRIP or $\alpha\beta$ RIP protein may be purified (as described above), and analyzed to determine the amino acid sequence of the proRIP or $\alpha\beta$ RIP. Any method capable of elucidating such a

sequence can be employed, however, Edman degradation is preferred. The use of automated sequencers is especially preferred.

It is possible to synthesize *in vitro* the proRIP and $\alpha\beta$ RIP from their constituent amino acids. A suitable technique includes the solid phase method (see Merrifield (1963), *J. Amer. Chem. Soc.*, **85**:2149-2154; and Solid Phase Peptide Synthesis (1969), (eds.) Stewart and Young). Automated synthesizers are also available.

The peptides thus prepared may be isolated and purified by procedures well known in the art (see Current Protocols in Molecular Biology (1989), (eds.) Ausubel, *et al.*, Vol. 1) and Sambrook *et al.* (1989), Molecular Cloning: A Laboratory Manual).

Using the amino acid sequence information, the DNA sequences capable of encoding them are examined in order to clone the gene encoding the proRIP. Because the genetic code is degenerate, more than one codon may be used to encode a particular amino acid.

Although it is possible to determine the entire amino acid sequence of the proRIP or $\alpha\beta$ RIP, it is preferable to determine the sequence of peptide fragments of the molecule, and to use such sequence data to prepare oligonucleotide probes which can be used to isolate the entire proRIP gene sequence. The proRIP peptide fragments can be obtained by incubating the intact molecule with cyanogen bromide, or with proteases such as papain, chymotrypsin or trypsin.

Using the genetic code one or more different oligonucleotides can be identified. The probability that a particular oligonucleotide will, in fact, constitute the actual proRIP encoding sequence can be estimated by considering abnormal base pairing relationships and the frequency with which a particular codon is actually used (to encode a particular amino acid) in eukaryotic cells. Using these rules, a single oligonucleotide, or a set of oligonucleotides, that contains a theoretical "most probable" nucleotide sequence capable of encoding the proRIP or $\alpha\beta$ RIP peptide sequences may be identified.

The oligonucleotide, or set of oligonucleotides, containing the theoretical "most probable" sequence capable of encoding the proRIP gene fragments may be used to identify the sequence of a complementary oligonucleotide, or set of oligonucleotides, which is capable of hybridizing to the "most probable" sequence, or set of sequences. An oligonucleotide containing such a complementary sequence can be employed as a probe to identify and isolate the toxin gene (see Sambrook *et al.* (1989), *supra*).

By hybridizing an oligonucleotide having a sequence complementary to the "most probable" gene sequence, one obtains a DNA molecule (or set of DNA molecules), capable of functioning as a probe to identify and isolate the proRIP gene.

The present invention also relates to DNA sequences that encode recombinant proRIP and $\alpha\beta$ RIP. The recombinantly-produced proRIP and $\alpha\beta$ RIP share the following properties with the proRIP and $\alpha\beta$ RIP isolated from nature and characterized according to the teachings herein: (1) portions of the amino acid sequence deduced from the nucleotide sequence are equivalent to amino acid sequences obtained directly from nature; (2) the polypeptide is recognized by anti-RIP antibodies; (3) the molecular weight of the proRIP and $\alpha\beta$ RIP polypeptides encoded corresponds with the naturally occurring proteins; (4) each proRIP protein is convertible to an $\alpha\beta$ RIP; and (5) each proRIP and $\alpha\beta$ RIP protein exhibits relatively equivalent ribosome inactivating activity.

The process for genetically engineering the proRIP or $\alpha\beta$ RIP according to the invention is facilitated through the cloning of genetic sequences which are capable of encoding the proRIP or $\alpha\beta$ RIP, or effectively homologous variants thereof as discussed below, and through the expression of such genetic sequences. As used herein, the term "genetic sequences" is intended to refer to a nucleic acid molecule (preferably DNA). Genetic sequences which are capable of encoding the toxin may be derived from a variety of sources. These sources include genomic DNA, cDNA, synthetic DNA, and combinations thereof.

Cells containing the desired sequence may be isolated, and genomic DNA fragmented by one or more restriction enzymes. The genomic DNA may or may not include naturally-occurring introns. The genomic DNA digested with selected restriction endonucleases yields fragments containing varying numbers of base pairs (bp).

Specifically comprehended as part of this invention are genomic DNA sequences encoding allelic variant forms of the proRIP gene which may include naturally occurring introns. The allelic gene may be derived using a hybridization probe made from the DNA or RNA of the proRIP gene as well as its flanking regions. "Flanking regions" are meant to include those DNA sequences 5' and 3' of the proRIP encoding sequences.

The DNA isolate encoding the proRIP gene may also be obtained from a cDNA library. The mRNA may be isolated from a suitable source employing standard techniques of RNA isolation, and the use of oligo-dT cellulose chromatography to enrich for poly-A mRNA. A cDNA library is then prepared from the mixture of mRNA using a suitable primer, preferably a nucleic acid sequence which is characteristic of the desired

cDNA. A single stranded DNA copy of the mRNA is produced using the enzyme reverse transcriptase. From the single stranded cDNA copy of the mRNA, a double-stranded cDNA molecule may be synthesized using either reverse transcriptase or DNA polymerase.

It is also possible to use primers to amplify the DNA from cells of appropriately prepared seeds and immature kernels by the polymerase chain reaction (PCR). PCR involves exponentially amplifying DNA *in vitro* using sequence specified oligonucleotides. (see Mullis *et al.* (1987), *Meth. Enz.*, 155:335-350; Horton *et al.* (1989), *Gene*, 77:61; and *PCR Technology: Principles and Applications for DNA Amplification*, (ed.) Erlich (1989).

The DNA encoding the proRIP or $\alpha\beta$ RIP may be chemically synthesized by manual procedures, e.g., the phosphotriester and phosphodiester methods (see Caruthers (1983), In: *Methodology of DNA and RNA*, (ed.) Weissman); or automated procedures e.g., using diethylphosphoramidites are used as starting materials (see Beaucage *et al.* (1981), *Tetrahedron Letters*, 22:1859-1962). The DNA may be constructed by standard techniques of annealing and ligating fragments or by other methods.

Thereafter, the desired sequences may be isolated and purified by procedures well known in the art (see *Current Protocols in Molecular Biology* (1989), *supra*) and Sambrook *et al.* (1989), *Molecular Cloning: A Laboratory Manual*.

The nucleotide sequence of the maize proRIP cDNA and the deduced amino acid sequence of such the corresponding maize proRIP is set forth in Table 1.

One need not be confined to the amino acid sequences of proRIP and $\alpha\beta$ RIP found in nature. Thus, it is possible to selectively produce both proRIP and $\alpha\beta$ RIP via the application of recombinant DNA technology. This in turn allows the production of sufficient quality and quantity of material to create novel forms of the protein unimpeded by the restriction necessarily inherent in the isolation methods involving production and extraction of the protein from natural sources.

Recombinant procedures make possible the production of effectively homologous proteins possessing part or all of the primary structural conformation and/or one or more of the biological properties of the $\alpha\beta$ RIP. For purposes of this invention, an amino acid sequence is effectively homologous to a second amino acid sequence if at least 70 percent, preferably at least 80 percent, and most preferably at least 90 percent of the active portions of the amino acid sequence are identical and retains its intended function. Thus more importantly and critical to the definition, an effectively homologous sequence to the $\alpha\beta$ RIP retains the capacity to interact with and inactivate eukaryotic ribosomes. The effectively homologous sequence to the proRIP must retain the capacity to be converted into an $\alpha\beta$ RIP. That is, the effectively homologous proRIP must have a linker sequence which, when cleaved, will yield a biologically functional $\alpha\beta$ RIP.

General categories of potentially-equivalent amino acids are set forth below, wherein, amino acids within a group may be substituted for other amino acids in that group: (1) glutamic acid and aspartic acid; (2) lysine, arginine and histidine; (3) hydrophobic amino acids such as alanine, valine, leucine and isoleucine; (4) asparagine and glutamine; (5) threonine and serine; (6) phenylalanine, tyrosine and tryptophan; and (7) glycine and alanine.

It is envisioned that, compared with changes to the α and β fragments, more significant changes may be made to the proRIP in the leader and linker regions. That is, since the leader and linker sequences are to be cleaved, the length and amino acid residues in their sequences may better be tolerated and considered insignificant, because it will not alter the functionality of the final product.

Further, the linker sequence of the proRIP need not be limited to the sequence set forth in Table 1, above. For example, the length of the linker may be modified, provided that (1) the linker is cleavable, and (2) upon cleavage of the linker the resultant protein has an IC_{50} value that is at least about 10 times lower than the IC_{50} value of the protein containing the linker.

Primary criteria for selecting an effectively homologous linker include altering the net charge of the $\alpha\beta$ RIP (e.g., more acidic); creating a conformational shift in the protein or providing steric hindrance to the active site of the protein.

As noted previously, the maize $\alpha\beta$ RIP, like other RIPs, is basic. However, the maize proRIP has a slightly acidic pI. Thus, it is preferred that any effectively homologous linker selected for the maize proRIP will be acidic.

The linker should be of a length which, while capable of altering the three-dimensional structure of the protein, when cleaved will permit the protein to retain most of the three dimensional features of the active $\alpha\beta$ RIP molecule.

To ensure that the linker is cleavable it is generally required that the conformation of the proRIP be such that the linker cleavage sites are readily accessible to a selected cleavage agent.

It is also envisioned that at least one restriction enzyme site may be engineered into the genetic sequence encoding an RIP, allowing DNA sequences encoding various polypeptide linkers to be inserted

into the gene and tested for their ability to create an inactive, yet activatable RIP.

Most commonly, cleavage will be effected outside of the replicative environment, for example, following harvest of microbial culture. Thus, when genetically modifying the proRIP, it may be preferable, in some instances, that the internal linker domain of the proRIP be retained, or altered so as to mimic the manner in which a natural, inactive proRIP liberates its active α and β fragments.

Any chemical or enzymatic method which recognizes a specific sequence or structure and causes an appropriate cleavage at a selected site may be utilized for the present invention. For example, it may be desirable to design carboxy termini and amino termini of the linker sequences that are subject to cleavage with selected agents. Exemplary such sequences Pro-Xxx-Gly-Pro (where Xxx is unspecified) which is selectively cleaved by collagenase; Ile-Glu-Gly-Arg which is selectively cleaved by Factor Xa; and Gly-Pro-Arg which is selectively cleaved by thrombin (see Nilsson *et al.* (1988), In: Advances in Gene Technology; Protein Engineering and Production, (ed.) Brew *et al.*).

A chemical or enzymatic method may not be suitable if its cleavage site occurs within the active amino acid sequences of the α and β fragments. That is, cleavage within the native amino acid sequence of the α and β fragments will generally have a greater likelihood of deleteriously affecting the enzymatic activity of the $\alpha\beta$ RIP. It is possible to select a specific cleavage sequence of only one amino acid residue so long as that residue does not occur in the amino acid sequences of the α and β fragments. It is preferred, however, to utilize a specific cleavage sequence which contains two or more amino acid residues, i.e., an extended specific cleavage sequence. This type of sequence takes advantage of the extended active sites of various enzymes. Additionally, by utilizing an extended specific cleavage sequence, it is highly probable that cleavage will only occur at the desired site and not at other sites within the protein.

The cleavage techniques discussed here are by way of example and are but representative of the many variants which will occur to the skilled artisan in light of the specification.

In some instances it may prove desirable to effect cleavage of the proRIP within the cell. For example, an expression vehicle with appropriate promoters may be provided with a DNA sequence coding for enzymes which convert the proRIP to the active form, operating in tandem with the other DNA sequence coding expression of the proRIP.

Further, as is well known, protein sequences may be modified by post-translation processing such as becoming associated with other molecules, for example, glycosides, lipids, or such inorganic ions as phosphate. The ionization status will also vary depending on the pH of the medium or the pH at which crystallization or precipitation of the isolated form occurs. Further, the presence of air may cause oxidation of labile groups, such as -SH. Thus, included within the definition of the proRIP and $\alpha\beta$ RIP, and fragments, thereof are all such modifications of a particular primary structure, e.g., both glycosylated and non-glycosylated forms, neutral forms, acidic and basic salts, lipid or other associated peptide forms, side chain alterations due to oxidation or derivatization, and any other such modifications of an amino acid sequence which would be encoded by the same genetic codon sequence.

Exemplary techniques for nucleotide replacement include the addition, deletion or substitution of various nucleotides, provided that the proper reading frame is maintained. Exemplary techniques include using polynucleotide-mediated, site-directed mutagenesis, i.e., using a single strand as a template for extension of the oligonucleotide to produce a strand containing the mutation (see Zoller *et al.* (1982), *Nuc. Acids Res.*, 10:6487-6500; Norris *et al.* (1983), *Nuc. Acids Res.*, 11:5103-5112; Zoller *et al.* (1984), *DNA*, 3:479-488; and Kramer *et al.* (1982), *Nuc. Acids Res.*, 10:6475-6485) and by using PCR, i.e., exponentially amplifying DNA *in vitro* using sequence specified oligonucleotides to incorporate selected changes (see PCR Technology: Principles and Applications for DNA Amplification, Erlich, (ed.) (1989); and Horton *et al.*, *supra*).

By appropriate choice of restriction sites, the desired DNA fragment may be positioned in a biologically functional vector which may contain appropriate control sequences not present in the selected DNA fragment. By "biologically functional" is meant that the vector provides for replication and/or expression in an appropriate host, either by maintenance as an extrachromosomal element or by integration into the host genome. A large number of vectors are available or can be readily prepared, and are well known to skilled artisans.

In general, vectors containing the appropriate promoters, which can be used by the host organism for expression of its own protein, also contain control sequences, ribosome binding sites, and transcription termination sites. Generally, the replicon and control sequences which are derived from species compatible with the host cell are used in connection with these hosts.

Finally, the vectors should desirably have a marker gene that is capable of providing a phenotypical property which allows for identification of host cells containing the vector.

When expressing the $\alpha\beta$ RIP, the DNA fragments encoding the α fragment and the β fragment may be

inserted into separate vectors, or into the same vector. Specifically, when the α and β fragments are contained in separate vectors, the host cells may be transformed via either cotransformation or targeted transformation techniques.

Construction of suitable vectors containing the desired coding and control sequences may be produced as follows.

Restriction endonucleases may be used as a means for inserting the DNA fragments containing the proRIP gene or $\alpha\beta$ RIP genes into an appropriate expression vehicle. Exemplary restriction enzymes include *Aat* II, *Bam* HI, *Eco* RI, *Hind* III, *Nde* I, *Spe* I, *Xba* I, *Sac* I, *Bgl* II, *Pst* I, *Sal* I and *Pvu* II.

Cleavage is performed by treating the expression vehicle with a restriction enzyme(s). In general, 10 μ g vector or DNA fragments is used with 10 units of enzyme in 100 μ l of buffer solution. Endonuclease digestion will normally be carried out at temperatures ranging from 37 degrees Centigrade (37° C) to 65° C, at a pH of 7 to 9. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturers. Time for the reaction will be from 1 to 18 hours.

After the restriction enzyme digestion is complete, protein may be removed by standard techniques (e.g., extraction with phenol and chloroform). The nucleic acid may be then recovered from the aqueous fraction by standard techniques.

The desired fragment is then purified from the digest. Suitable purification techniques include gel electrophoresis or sucrose gradient centrifugation. The vector and foreign DNA fragments may then be ligated with DNA ligase.

An appropriately buffered medium containing the DNA fragments, DNA ligase, and appropriate cofactors is employed. The temperature employed will be between 4° C to 25° C. When DNA segments hydrogen bond, the DNA ligase will be able to introduce a covalent bond between the two segments. The time employed for the annealing will vary with the temperature employed, the nature of the salt solution, as well as the nature of the sticky ends or cohesive termini. Generally, the time for ligation may be from 5 to 18 hours (see Sambrook *et al.* (1989), *supra*).

Thereafter, the vector constructions may be used to transform an appropriate host cell. Suitable host cells include cells derived from unicellular as well as multicellular organisms which are capable of being grown in cultures or by fermentation.

Various unicellular microorganisms can be used for both cloning and expression. Prokaryotes include members of the Enterobacteriaceae, such as strains of *Escherichia coli*, and *Salmonella*; Bacillaceae, such as *Bacillus subtilis*; *Pneumococcus*, *Streptococcus*, and *Haemophilus influenzae*.

In addition to prokaryotes, eukaryotic cells may be employed. As previously stated, eukaryotic cells have not heretofore been used as recombinant host cells for RIPs. By providing inactive forms of RIPs, the present invention provides skilled artisans with the flexibility to use eukaryotic cells as recombinant hosts. By transforming eukaryotic cells with the proRIP gene, the protein may be expressed at high levels without being toxic to the host cell. Since the protein is lacking in bioactivity pending extra-cellular cleavage, the effect is to enhance the biosafety of the procedure. The proRIP may then be selectively chemically or enzymatically converted to the desired $\alpha\beta$ RIP.

Exemplary eukaryotic microbes include yeast, *Saccharomyces cerevisiae*, or common baker's yeast, is the most commonly used among eukaryotic microorganisms, although a number of other hosts are commonly available.

In addition to eukaryotic microbes, cultures of cells derived from multicellular organisms may also be used as hosts. Examples of useful host mammalian cell lines are Sp2/O, VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, and W138, BHK, COS-7 and MDCK cell lines.

Other suitable hosts and expression systems are the baculovirus systems maintained in cultured insect cells, e.g., from *Spodoptera frugiperda*.

Finally, cells from and portions of higher plants have been found useful as recombinant hosts, and appropriate control sequences are available for expression in these systems. Suitable plant cells include cells derived from, or seedlings of, tobacco, petunia, tomato, potato, rice, maize and the like.

The expression vehicle may be inserted into the host cell by any suitable method. Conventional technologies for introducing biological material into living cells include electroporation (see Shigekawa and Dower (1988), *Biotechniques*, 6:742; Miller, *et al.* (1988), *Proc. Natl. Acad. Sci. USA*, 85:856-860; and Powell, *et al.* (1988), *Appl. Environ. Microbiol.*, 54:655-660); direct DNA uptake mechanisms (see Mandel and Higa (1972), *J. Mol. Biol.*, 53:159-162; Dityatkin, *et al.* (1972), *Biochimica et Biophysica Acta*, 281:319-323; Wigler, *et al.* (1979), *Cell*, 16:77; and Uchimiya, *et al.* (1982), In: *Proc. 5th Intl. Cong. Plant Tissue and Cell Culture*, A. Fujiwara (ed.), Jap. Assoc. for Plant Tissue Culture, Tokyo, pp. 507-508); fusion mechanisms (see Uchidaz, *et al.* (1980). In: *Introduction of Macromolecules Into Viable Mammalian Cells*, Baserga *et al.* (eds.) Wistar Symposium Series, 1:169-185); infectious agents (see Fraley, *et al.* (1986), *CRC Crit.*

Rev. Plant Sci., 4:1-46; and Anderson (1984), *Science*, 226:401-409); microinjection mechanisms (see Crossway, *et al.* (1986), *Mol. Gen. Genet.*, 202:179-185); and high velocity projectile mechanisms (see EPO 0 405 696 to Miller, Schuchardt, Skokut and Gould, (The Dow Chemical Company)). The appropriate procedure may be chosen in accordance with the plant species used.

Generally after transformation, the host cells may be grown for about 48 hours to allow for expression of marker genes. The cells are then placed in selective medium and/or screenable media, where untransformed cells are distinguished from transformed cells, either by death or a biochemical property.

The transformed cells are grown under conditions appropriate to the production of the desired protein, and assayed for expression thereof. Exemplary assay techniques include enzyme-linked immunosorbent assay, radioimmunoassay, or fluorescence-activated cell sorter analysis, immunohistochemistry and the like.

Selected positive cultures are subcloned in order to isolate pure transformed colonies. A suitable technique for obtaining subclones is via the limiting dilution method.

Uses

Essentially all of the uses that the prior art has envisioned for RIPs are intended for the novel $\alpha\beta$ RIP and proRIP set forth herein (see *Immunotoxins* (1988), Frankel (ed.); and U.S. Patent 4,869,903 to Lifson *et al.* (Genelabs Incorporated and the Regents of the University of California)).

By providing inactive precursor forms of the $\alpha\beta$ RIP, it is now possible to provide protein synthesis inhibitors with uses in practical and improved ways not before possible. The inactive form of the $\alpha\beta$ RIP offers the additional advantage, over active RIPs, of not being active until removal of the linker sequence. Although the RIP is not toxic to the majority of mammalian cells it is known that RIP may be made specifically cytotoxic by attachment to a targeting vehicle which is capable of binding to and into target cells.

Exemplary targeting vehicles include any peptide hormone, growth factor, or other polypeptide cell recognition protein for which a specific receptor exists. A few examples include: antibodies and antibody fragments, lectins, insulin, glucagon, endorphins, growth hormone, melanocyte-stimulating hormone, transferrin, bombesin, low density lipoprotein, luteinizing hormone and asialoglycoprotein that bind selectively to target cells (see *Immunotoxins* (1988), *supra*). It is well established that conjugates which contain RIP exhibit maximal cytotoxicity only when the RIP moiety is released from the targeting vehicle.

Since the $\alpha\beta$ RIP and proRIP does not contain a reactive sulfhydryl group, it may be necessary to modify the proteins using chemical crosslinking reagents in order to link such proRIP and $\alpha\beta$ RIP to targeting vehicles.

Conjugates of a monoclonal antibody and the $\alpha\beta$ RIP and proRIP may be made using a variety of bifunctional protein coupling agents. General examples of such reagents are N-succinimidyl-3-(2-pyridyldithio)propionate, 2-iminothiolane, bifunctional derivatives of imidoesters such as dimethyl adipimidate, active esters such as disuccinimidyl suberate, aldehydes such as glutaraldehyde, bis-azido compounds such as bis(p-diazoniumbenzoyl)ethylenediamine, diisocyanates such as toluene 2,6-diisocyanate, and bis-active fluorine compounds such as 1,5-difluoro-2,4-dinitrobenzene (see, for example, WO 86/05098).

In addition, recombinant DNA methodologies may be employed to construct a cytotoxic fusion protein. For a general discussion of chimeric toxins (see, for example, Pastan and FitzGerald (1989), *The Journal of Biological Chemistry*, 264:15157-15160; and U.S. Patent 4,892,827 to Pastan *et al.* (The United States of America as represented by the Department of Health and Human Services)). These references teach modified *Pseudomonas* exotoxins which comprise a deletion in a receptor binding domain to form a fusion protein capable of rendering the modified toxin less toxic to selected cells. These references teach DNA sequences encoding the human alpha transforming growth factor (α -TGF) or human interleukin fused to toxin genes.

Examples

The present invention is illustrated in further detail by the following examples. The examples are for the purposes of illustration only, and are not to be construed as limiting the scope of the present invention. All temperatures not otherwise indicated are Centigrade. All parts and percentages are by weight unless otherwise specifically noted.

Example 1: Isolation of Maize $\alpha\beta$ RIP

All steps were performed at 4° C, except for high performance liquid chromatography (HPLC) which was

performed at room temperature. Five hundred grams (500 g) of finely ground mature maize kernels were extracted for at least 2 hour and up to 24 hours (hr) with 1500 ml, 25 mM sodium phosphate, pH 7.2 (PB) + 50 mM sodium chloride. After the extract was strained through several layers of cheesecloth, the protein precipitating between 55 percent and 85 percent ammonium sulfate was collected and redissolved in PB, then dialyzed overnight against the same buffer. The solution was clarified by centrifugation and applied to a 2.5 x 10 centimeter (cm) DE-52 cellulose column equilibrated with PB. The protein passing straight through the column was collected and applied to a Mono S 10/10 column (Pharmacia LKB Biotechnology, Piscataway, NJ) equilibrated with PS, and eluted with a linear gradient of 0 to 200 mM sodium chloride in PB over 90 min at 2 milliliter/ minute (ml/min). Alternatively, the protein can be precipitated with 85 percent ammonium sulfate and dialyzed overnight before applying to the Mono S 10/10 column.

Fractions containing ribosome inactivating protein activity (as measured by rabbit reticulocyte protein synthesis assay, described above) were pooled and concentrated to 0.5 ml in Centricon-10 devices (Amicon, Danvers, MA), and applied to a Superose 12 column equilibrated in PB (Pharmacia LKB Biotechnology) at a flow-rate of 0.4 ml/min. Fractions containing ribosome inactivating protein activity (as measured by a rabbit reticulocyte protein synthesis assay, described above) (the first major peak) were pooled. At this stage, the $\alpha\beta$ RIP was usually quite pure as identified by SDS-PAGE (see Laemmli (1970), *supra*). If necessary, further purification can be achieved by applying the protein to a Mono S 5/5 column (Pharmacia LKB Biotechnology) equilibrated with PB and eluted at 1 ml/min with 0 to 50 mM sodium chloride in PB over 5 min, then 50 to 200 mM sodium chloride in PB over 25 min.

Results from a typical purification are presented in Table 5. The effect of purified maize $\alpha\beta$ RIP on mammalian protein synthesis is shown in Figure 2.

Table 5

Purification of maize RIP from mature kernels

Step	Protein (mg)	Total units ¹ x 10 ⁶	Yield (%)	Fold Purification	IC ₅₀ (ng/ml)
Crude extract	6816	384	100	1.0	323
85% Ammonium sulfate	1010	115	30	2.0	161
post-DE52 treatment	428	144	38	5.9	54
Mono S 10/10 pool	10.2	58	15	102	3.2
Superose 12 pool	1.8	33	8.6	327	0.99
Mono S 5/5 pool	1.32	32.4	8.4	436	0.74

1. One unit of activity is the amount of protein required to produce 50% inhibition in the rabbit reticulocyte lysate protein synthesis assay.

A. Rabbit Reticulocyte Cell-Free Protein Synthesis Assay

The inhibitory activity of the maize $\alpha\beta$ RIP toward mammalian protein synthesis was measured in a

rabbit reticulocyte lysate system following the procedures of Pelham and Jackson (see (1976), Eur. J. Biochem., 67:247-256).

A mix of the following reagents was prepared (2.5 milliliter (ml) total volume): 125 microliter (μ l) 200 mM Tris-HCl, pH 7.6 + 40 mM magnesium acetate + 1.6 M potassium chloride; 12.5 μ l 3 mM hemin hydrochloride in 50 percent ethylene glycol; 1.0 ml untreated rabbit reticulocyte lysate (Promega, Madison, WI); 1.0 ml H₂O; 62.5 μ l amino acid mix; 125 μ l 20 mM ATP + 4 mM GTP; 125 μ l 200 mM creatine phosphate; 50 μ l 2.5 mg/ml creatine phosphokinase in 50 percent ethylene glycol. The amino acid mix contained 50 μ M of each amino acid except glycine (100 μ M), arginine, isoleucine, methionine and tryptophan (10 μ M each) and contained no leucine. All stock solutions were previously adjusted to pH 7.5 prior to addition.

Five microliters (5 μ l) of appropriate dilutions of samples to be assayed were placed in the wells of a 96-well plate and 50 μ l of the mix added. After 10 minutes, 50 nanoCuries (nCi) ¹⁴C-leucine in 10 μ l was added to each well. After a further 10 minutes (min.), the reaction was quenched with 10 μ l 1.5 M potassium hydroxide and incubated for 45 min. Twenty-five microliters (25 μ l) of each sample was then pipetted onto individual 2.1 cm Whatman 3 MM paper disks (Whatman, Clifton, NJ) and after drying for 2 to 3 min, the disks were washed successively by swirling in a flask with 250 ml 10 percent trichloroacetic acid, 250 ml 5 percent trichloroacetic acid (twice), 125 ml ethanol, 250 ml 1:1 ethanol/acetone, and 125 ml acetone. After drying, the filters were placed in vials with 10 ml scintillation cocktail and counted.

20 B. Antisera and Western blot analysis:

The α and β polypeptide bands were cut from 3 millimeter (mm) SDS-PAGE gels after brief staining with Coomassie blue and were electroeluted using an electroelution device (Bio-Rad, Richmond CA) according to the manufacturer's directions. The polypeptide preparations were then used to immunize rabbits to yield polyclonal anti-sera (prepared by RIBI Immunochem, Montana).

Western blots from PhastgelsTM reagent (Pharmacia LKB Biotechnology) were performed by removing the gel from the plastic backing and then electroblotting onto Immobilon paper (Millipore Corporation, Bedford, MA). Blots were developed using the maize $\alpha\beta$ RIP primary antiserum at 1:2000 dilution and alkaline phosphatase-conjugated goat anti-rabbit secondary antibody (Bio-Rad), according to the manufacturer's instructions.

Example 2: Isolation of Maize proRIP

The polyclonal antisera against the α and β fragments were used to identify a common 34 kD precursor polypeptide in crude extracts of maize kernels (maize proRIP). The presence of the maize proRIP was monitored during subsequent purification by Western blot analysis as set forth above. All steps of the purification were performed at 4°C, except for HPLC which was performed at room temperature.

Two hundred fifty grams (250 g) of immature maize kernels were homogenized in 600 ml 25 mM sodium phosphate, pH 7.2 (PB) + 5 μ g/ml antipain. After the extract was strained through several layers of cheesecloth, the protein precipitating between 45 and 80 percent ammonium sulfate was collected and redissolved in 15 ml PB, then passed over a 2.5 x 15 cm Sephadex G-25 column (Pharmacia LKB) equilibrated in PB. Fractions containing protein were pooled and diluted to ~60 ml with water. The solution was applied to a Q-Sepharose (fast-flow) column packed in a 10/10 FPLC column (Pharmacia LKB Biotechnology) equilibrated with PB, and eluted with a 0 to 300 mM NaCl gradient at 2 ml/min over 75 min. Fractions containing the 34 kD precursor were pooled and concentrated by a Centriprep 10 device (Amicon) to 1.5 ml. This was diluted four-fold with water and applied to a Mono Q 5/5 column (Pharmacia LKB Biotechnology) equilibrated in PB. The column was eluted with a 0 to 250 mM NaCl gradient over 60 min. Fractions containing the 34 kD polypeptide were pooled, concentrated to 0.5 ml and applied to a Superose 12 column (Pharmacia LKB Biotechnology) equilibrated in PB. The major peak from this column contained the 34 kD maize RIP precursor and appropriate fractions were pooled and stored at -20°C.

Example 3: PAGE Analysis of Maize $\alpha\beta$ RIP and proRIP

SDS-PAGE was performed with a PhastsystemTM reagent (Pharmacia LKB Biotechnology) using 20 percent PhastgelsTM reagent and following the manufacturer's instructions. Native PAGE was performed at pH 4.2 as described in the PhastsystemTM reagent application file no. 300, method 1 (Pharmacia LKB Biotechnology).

SDS-PAGE of highly purified, active maize $\alpha\beta$ RIP exhibited two polypeptides an α fragment (16.5 kD)

and a β fragment (8.5 kD) under both reducing and non-reducing conditions. A single band was seen in native PAGE analysis of purified, active maize $\alpha\beta$ RIP. The minimal Mr value of the associated, native maize $\alpha\beta$ RIP was therefore 25 kD.

By SDS-PAGE, highly purified maize proRIP migrated with a value of 34 kD.

Example 4: *In vitro* activation of Maize proRIP by Papain

A purified sample of proRIP was incubated at 0.5 mg/ml with papain, a plant thiol protease, at 0.01 mg/ml in sodium acetate buffer, pH 6 containing 2 mM dithiothreitol. After 1 to 2 hours at room temperature, the 34 kD proRIP was digested to a stable product exhibiting a polypeptide pattern almost identical to that of native, active maize $\alpha\beta$ RIP. There was a concomitant increase in ribosome inactivating activity in the incubation; the undigested proRIP had no ribosome inactivating activity up to 2 μ g/ml, whereas papain-treated proRIP had an IC₅₀ of <80 ng/ml. In contrast trypsin had no effect on maize proRIP.

Example 5: Chemically-determined amino acid sequences

A. N-Terminal Amino Acid Sequences of Maize $\alpha\beta$ RIP α fragment and β

A sample of maize $\alpha\beta$ RIP was electrophoresed by the method of Laemmli (1970), *supra* in 1.5 mm thick gels and the gel electroblotted onto Immobilon PVDF paper (Millipore) using a Transphor™ apparatus (Pharmacia LKB Biotechnology). The paper was stained briefly with Coomassie blue and the bands corresponding to the 16.5 and 8.5 kD polypeptides were cut out. These were N-terminal sequenced directly from the PVDF paper using an 470A gas phase sequencer (Applied Biosystems, Foster City, CA). The following data was obtained (bracketed residues denote lower confidence assignments):

N-Terminal sequence of α fragment:

K R I V P K I T E I F P V E D A N Y P V S A F I A [G] V X
K D V I

An additional minor species (~20 percent of the total species) had an N-Terminal sequence of:

A Q T N K[L]I V P K

N-Terminal sequence of β fragment:

A A D P Q A D T K S X L V K L V V M S/C E G L X F N T V
S

B. α fragment C-Terminal Amino Acid Sequence

The carboxy-terminal amino acid sequence of the α maize $\alpha\beta$ RIP α fragment was determined using sequencing grade carboxypeptidase P from *Penicillium japonicum* (Boehringer Mannheim, Indianapolis, IN). A sample of 16.5 kD polypeptide was purified by reverse-phase HPLC using a Vydac 5 μ C4 4.6 x 30 mm RP column. The column was equilibrated with 0.1 percent trifluoroacetic acid (TFA), and eluted with 0 to 40 percent of 0.1 percent TFA + 80 percent acetonitrile over 8 min, then 40 to 60 percent of 0.1 percent TFA + 80 percent acetonitrile over 20 min. The β fragment eluted after 21.9 min. and the α fragment eluted after 23.3 min.

A lyophilized sample of the α fragment was dissolved in 20 mM sodium acetate, pH 5.8 + 4 M urea. The digestion mix contained the following in 0.1 ml: 1.6 μ g carboxypeptidase P, 66 μ g β fragment, 0.12 M sodium acetate pH 4.2, 0.8 M urea. After 1, 5, 15, 60, 120 and 480 min, duplicate 8 μ l aliquots from the digestion were added to 8 μ l 0.4 M sodium borate, pH 10.5 and frozen on dry ice.

Amino acid analysis was performed essentially as described by Jones (1986), In: *Methods of Protein Microcharacterization*. (ed.) J.E. Shively. The following sequence is obtained: $\text{NH}_2\text{-Asp-Leu-Ala-(Lys)}_n\text{-COOH}$, where $n = 2-4$. This was the carboxy terminus of the α polypeptide, therefore this and the N-terminus sequence of the β fragment define the linker region contained in the precursor (see amino acid sequence derived from cDNA in Table 1).

C. N-Terminal Amino Acid Sequence of Maize proRIP

No N-Terminal sequence data was obtained from a sample of the 34 kD maize proRIP indicating that this polypeptide is N-terminal blocked.

Example 6: Isolation and Characterization of cDNA for Maize proRIP

A. Isolation

Immature kernels from field grown Pioneer hybrid 3737 were harvested, shelled from the cob, and stored at -20°C . Ten grams (10 g) of kernels were frozen in liquid nitrogen for several minutes then ground to a powder in a Waring blender. The powder was suspended in 20 ml of ice cold TENS buffer (10 mM Tris pH 7.4, 1 mM EDTA, 0.5 percent SDS, 0.3 M NaCl) and extracted immediately with an equal volume of phenol-chloroform-isoamyl alcohol (25:24:1) saturated with TENS buffer. The aqueous phase was collected and extracted three more times with fresh phenol mixtures.

Nucleic acids were precipitated from the aqueous phase by adjusting it to 0.3 M sodium acetate pH 5.5 and adding 2.5 volumes of 100 percent ethanol. Nucleic acids were collected by centrifugation and suspended directly in 1 ml phenol-chloroform-isoamyl alcohol plus 1 ml TENS and extracted by vortexing. The nucleic acid was precipitated from the aqueous phase by ethanol precipitation as above. The precipitate was collected by centrifugation and resuspended in TE buffer (10 mM Tris pH 7.4, 1 mM EDTA). Single strand nucleic acid was precipitated by adjusting the solution to 2M LiCl and incubating for 4 to 12 hours at 4°C . Centrifugation yielded a pellet which consisted of between 2.2 to 2.5 mg of total RNA.

Poly(A)-containing RNA was enriched from the total RNA sample by using Hybond mAPTM mRNA purification affinity paper (Amersham Corporation, Arlington Heights IL). The supplier's protocol was followed. Typically 5 to 10 μg of poly(A) enriched RNA were recovered per milligram of total RNA.

Five micrograms (5 μg) of poly(A) enriched RNA were converted into double stranded cDNA using a cDNA SynthesisTM kit (Pharmacia LKB Biotechnology). The cDNA was ligated into the cloning vector Lambda gt11 (Stratagene Inc., La Jolla CA) following the supplier's instructions. Packaging of the ligated vector-insert mixture was done with the Gigapack plus packaging extract (Stratagene, Inc.) again following the supplier's protocol.

The PicoBlue ImmunodetectionTM kit (Stratagene, Inc.) was used to screen the Lambda gt11 maize kernel cDNA library using rabbit polyclonal antisera raised against the maize proRIP, as described above.

Positive clones were purified to homogeneity and the cDNA inserts characterized by *Eco* RI restriction enzyme analysis. One of the largest *Eco* RI generated cDNA inserts (about 1,100 bp) was ligated into the *Eco* RI site of plasmid pUC19 (Bethesda Research Labs, Gaithersburg, MD). Clones carrying the proRIP cDNA insert in both orientations were identified by restriction digestion and used for large scale plasmid purification.

B. Sequencing the maize proRIP cDNA

The nucleotide sequence of the proRIP cDNA (set forth in Table 1) was determined by dideoxy chain termination sequencing using the SequenaseTM DNA sequencing kit (United States Biochemical Corp., Cleveland Ohio). The double stranded pUC19-RIP was used as template following the manufacturer's instructions. The first round of sequencing was initiated by the M13/pUC forward sequencing primer (Bethesda Research Labs). Subsequent primers were derived from the sequenced maize proRIP cDNA. Both strands of the cDNA were fully sequenced at least once.

The open reading frame encoding the $\alpha\beta$ RIP protein was confirmed by comparing the cDNA deduced amino acid sequence (set forth in Table 1) to the chemically determined protein sequence data.

Example 7: Expression of Maize proRIP and Derivatives in *Escherichia coli*

Various genetic derivatives of maize proRIP may be expressed in *E.coli* and tested for ribosome

inactivating activity. A summary of several constructions and their properties is given below.

A. R34 (set forth in Table 6 below) represents the intact recombinant proRIP gene which encodes a protein of Mr 33,327 and as expected is not a potent inhibitor of protein synthesis. Upon papain treatment it is processed into two associated polypeptides (of approximately 17 + 9 kD) by SDS Phastgel™ analysis) with very potent ribosome inactivating activity. N34 represents the native proRIP as isolated from nature.

Table 6

R34 DNA Sequence: The Maize ProRIP DNA Engineered for Expression in *Escherichia coli*

```


1  GCTTAATTAA TTAAGCTTAA AAGGAGGAAA AAAATTATGG CCGAGATAAC CCTAGAGCCC
51 AGTGATCTTA TGGCGCAAAC AAACAAAAGA ATAGTGCCAA AGTTCACCTGA AATCTTCCCC
121 GTGGAGGACG CGAACTACCC TTACAGCGCC TTCATCGCGT CGGTCCGGAA AGACGTGATC
181 AAACACTGCA CCGACCATAA AGGGATCTTC CAGCCCGTGC TGCCACCGGA GAAGAAGGTC
241 CCGGAGCTAT GGTCTACAC AGAGCTCAAA ACTAGGACCA GCTCCATCAC GCTCGCCATA
301 CGCATGGACA ACCTGTACCT CGTGGGCTTC AGGACCCCGG GCGGGGTGTG GTGGGAGTTC
361 GGCAAGGACG GCGACACCCA CCTCCTCGGC GACAACCCCA GGTGGCTCGG CTTCGGCGGC
421 AGGTACCAGG ACCTCATCGG CAACAAGGGT CTGGAGACCG TCACCATGGG CCGCGCCGAA
481 ATGACCAGGG CGGTCAACGA CTTGGCGAAG AAGAAGAAGA TGGCGACACT GGAGGAGGAG
541 GAGGTGAAGA TGCAGATGCA GATGCCCGAG GCCGCTGATC TGGCGGCGGC GGCAGCGGCT
601 GACCCACAGG CCGACACGAA GAGCAAGCTG GTGAAGCTGG TGGTCATGGT GTGCGAGGGG
661 CTGCGGTTC AACCCTGTG CCGCACGGTG GACGCGGGGT TCAACAGCCA GCACGGGGTG
721 ACCTTGACCG TGACCCAGGG GAAGCAGGTG CAGAAGTGGG ACAGGATCTC CAAGGCGGCC
781 TTCGAGTGGG CTGACCAACC CACCGCTGTG ATCCCGGACA TGCAGAAGCT TGGCATCAAG
841 GATAAGAAGC AAGCAGCGAG GATCGTTGCG CTCGTTAAGA ATCAAACCTAC TGCCGCTGCC
901 GCTACTGCTG CCAGTGCTGA CAACGACGAC GACGAGGCCT GATCAATGCA ACGACACATC
961 ATGATCTGCT GTTGCACCTA ATTACTATGT TCGTATACAA ATAAATACAC CCGGCGTACG
1021 CCGTGTTCCT TATATGGTCT AAAATGTAGC CAGTAAATTT TAAACTACTT TCTCGTGGCG
1081 AATTCACCTG CCGGATAGCT ATATA

```

Expression of the recombinant maize proRIP in *E. coli* was accomplished by engineering the cDNA via PCR amplification. A 5' primer was synthesized which contained termination codons in all three reading frames to stop translation of vector-encoded proteins upstream of the maize proRIP cDNA. The primer also contained a Shine-Dalgarno sequence several base pairs upstream of an ATG start codon followed by 23 bases which were homologous to the maize proRIP cDNA. The 3' primer spans the 3' cDNA end-pUC19 junction (the primers were shown by the underlined regions set forth in Table 6). PCR amplification of the cDNA in pUC19 using the GeneAmp™ kit (Perkin Elmer-Cetus, Norwalk, CT) yielded a predominant amplification product of approximately 1100 base pairs, as expected.

The engineered, amplified product, was purified from an agarose gel and ligated into the filled-in *Hind* III

site of the expression vector pGEMEX-1 (Promega Corp., Madison, WI) to give plasmid pGR, set forth below.




This was transformed into *E. coli* DH5 α (Bethesda Research Labs). Plasmids containing the maize proRIP cDNA were isolated by colony hybridization (see Sambrook *et al.*, *supra*) with a 5' maize proRIP cDNA probe and characterized. Those containing the cDNA probe for the maize proRIP in the correct orientation were tested for expression. Plasmids were transformed into competent *E. coli* JM109(DE3) (Promega Corp., Madison, WI), transformed cells were grown in 15 ml cultures under ampicillin selection to an optical density at 600 nm of 0.4 to 1.0. Isopropylthio- β -galactoside (IPTG) was added to 1.3 mM to induce the production of recombinant proRIP and the cultures were grown an additional 4 hours at 37 $^{\circ}$ C. The cells were collected by centrifugation and stored as a pellet at -20 $^{\circ}$ C.

The protein produced from the maize proRIP cDNA was analyzed by lysing the induced cells in TE containing 1 mg/ml lysozyme 37 $^{\circ}$ C for 15 min. The lysate was fractionated into a crude supernatant and pellet by microcentrifugation. The fractions were analyzed by SDS-PAGE using 20 percent PhastgelsTM reagent (Pharmacia LKB Biotechnology). Coomassie blue staining and Western blot analysis of the gels with anti-maize proRIP sera identified a 34 kD band which was greatly increased upon induction of the cells with IPTG. Cells not carrying the plasmid or containing the plasmid with the maize proRIP cDNA in the inverted orientation did not contain this 34 kD immuno-reactive band. The majority of the recombinant maize proRIP was contained in the cellular pellet suggesting the material was insoluble under these conditions.

To test if R34 could acquire the folding pattern of N34 the pellet fraction of an induced culture was dissolved in 6M guanidine HCl and allowed to denature at room temperature for 3 hours. The material was then diluted 200-fold into ice cold TE and incubated at 4 $^{\circ}$ C overnight to allow refolding of the denatured R34. The diluted material was then concentrated by a Centricon 10 device (Amicon). To test whether refolded R34 could undergo the correct proteolytic processing to the fragmented form of the maize proRIP, the material was treated with 10 μ g/ml papain for various times, and samples were analyzed by SDS-Phastgel and Western blot analysis. The R34 material was processed to a stable mixture of two immuno-reactive bands which comigrate with N34 papain-processed material indicating the correct proteolytic processing had occurred.

In an effort to simplify purification of the R34 polypeptide from induced lysates, the gene 10 coding region of the pGEMEX-1 vector was removed by cutting the maize proRIP gene-containing plasmid (pGR) with *Xba*I and gel purifying the vector/proRIP DNA away from the gene 10 encoding DNA. Recircularization of pGR, now minus the gene 10 coding region, resulted in a plasmid called pGR1 set forth below.



The plasmid pGR1 was transformed into JM109(DE3) cells and tested for production of R34 following induction with IPTG. As with pGR, large amounts of R34 were identified in cellular lysates both by Western blot and Coomassie blue staining. Unlike pGR, R34 produced from pGR1 was soluble and fractionated in the supernatant of lysed cells. This soluble material was treated with papain at 10 μ g/ml and the R34 produced from pGR1 was cleaved to products which comigrate with N34, papain-cleaved product. The papain-treated material inhibited translation of reticulocyte lysates at significantly higher dilutions than the untreated material, indicating that the soluble R34 was processed to an active form.

B. R34-DL represents the proRIP without the linker. The sequences encoding α and β were joined directly without intervening linker DNA, i.e., nucleotides A-520 to A-594 are deleted. The R34-DL gene encoded a 30.6 kD protein which was a potent inhibitor of protein synthesis. Treatment of R34-DL with papain resulted in a 28 kD polypeptide with increased ribosome inactivating activity over the untreated molecule.

Confirmation that removal of the linker from maize proRIP activated the molecule was obtained independently through genetic engineering. The 75 bp linker encoding region of R34 (A-520 to A-594 inclusive, Table 6) was deleted using PCR amplification. The new construction R34-DL joined directly, in frame, the DNA encoding both the α and β fragments.

In the pGEMEX-1 system the R34-DL gene directed the synthesis of a polypeptide approximately 30.6 kD, which was recognized by antisera specific for the maize proRIP. At high dilution, *E. coli* lysates containing R34-DL protein were potent inhibitors of protein synthesis in rabbit reticulocyte lysates, in marked contrast to *E. coli* lysates containing the R34 polypeptide.

These genetic deletion data confirm that removal of the linker served to activate the R34 (proRIP) molecule. This experiment also demonstrated that covalent linkage of the α and the β polypeptide fragments resulted in an active $\alpha\beta$ RIP. The maize proRIP did not require a break in the polypeptide backbone for enzymatic activity, removal of the linker region was sufficient to confer potent ribosome inactivating activity.

In addition, when R34-DL lysates were treated with papain a slight decrease in the molecular weight of R34-DL protein is noted (from 30.6 kD to approximately 28 kD). The R34-DL polypeptide remained intact, that is, it was not cleaved to the characteristic maize $\alpha\beta$ RIP α and β fragments. Associated with this small change in molecular weight was an increase in protein synthesis inhibition in the *E. coli* lysates. These data indicated that in bacterial lysates removal of the linker region activated the ribosomal inactivating activity of the protein at least 250-fold, but that additional processing from the ends of the protein increased the activity.

Another genetic construction was made using PCR technology to remove the leader region from R34-DL. The new construction called R30-DL (nucleotides C-40 to C-84 and A-520 to A-594 inclusive are deleted) encoded a protein (approximately 29.5 kD) which was slightly smaller than R34-DL. *E. coli* lysates containing R30-DL appeared to be even more potent inhibitors of protein synthesis than R34-DL lysates. Papain treatment of R30-DL containing lysates further enhanced protein synthesis inhibiting activity. Following this treatment the R30-DL protein underwent a slight decrease in molecular weight representing processing at the ends of the polypeptide..

Example 8:

A segment of the R30-DL gene was deleted which encodes several acidic residues at the carboxy terminus of the protein. The deletion was accomplished using the PCR engineering methods.

A thermocycler (Perkin-Elmer Cetus, Norwalk, CT) was used for the indicated constructions. A typical run was done with a one minute denaturation step, 2 minute annealing, and a 3 minute extension step. Temperatures used were 94°C, 37°C or 50°C, and 72°C respectively. Following 25 cycles the reaction was held at 72°C for 7 minutes for extension of unfinished products.

Amplification engineering reactions were done in four separate tubes of 100 µL each. The tubes were combined following amplification. Normally 100 ng of template was included in each tube. DNA primers were synthesized on a PCR Mate or 380A DNA synthesizer (Applied Biosystems) and were purified on acrylamide gels. Fifty (50) pmol of each primer were included in each reaction. The reaction conditions for the amplification were those recommended by Perkin Elmer Cetus (10 mM Tris-HCl pH8.3, 50 mM KCl, 1.5 mM MgCl₂, 0.001 percent gelatin, 200 µM dNTPs and 2.5 units of *Taq* DNA polymerase or AmpliTaq™ thermostable DNA polymerase).

Several methods of genetic engineering were employed to produce the genetic derivatives described below. The standard methods of DNA purification, restriction enzyme digestion, agarose gel analysis, DNA fragment isolation, ligation and transformation were as described (see Molecular Cloning: A Laboratory Manual, *supra* and Current Protocols in Molecular Biology, (1987), *supra*).

Enzymes used for the engineering were from one of three manufacturers (Pharmacia LKB Biotechnology; Bethesda Research Labs; or New England Biolabs, Beverly, MA). Buffers and protocols used were provided by the manufacturer.

Using PCR introduced engineering, a modified RIP fragment is amplified from an RIP plasmid template, purified, then used to replace the unmodified region in the RIP gene. All fragment replacements were done in RIP genes already inserted into a pGEMEX expression plasmid.

A pGEMEX plasmid containing R30-DL, which had the 3' half of the gene removed by *Nco* I and *Stu* I digestion followed by gel purification was used as the template for PCR. The 3' half of the RIP gene was replaced with the PCR modified fragment described below.

A 3' PCR primer was synthesized which encoded the 7 amino acid deletion near the carboxy terminus and introduced a new unique *Bam* HI site. The 5' primer directed the deletion of the αβ linker and included a *Nco* I site. The sequences of these primers is given in Table 7. The primers were used to amplify a modified DNA fragment from a pGEMEX R34-DL template. The amplified fragment was phenol extracted and ethanol precipitated. The insert DNA was cut with *Nco* I and ligated into the pGEMEX-R30-DL vector.

Table 7

Polymerase Chain Reaction primers for RDT.

Table 7: Polymerase Chain Reaction primers for RDT.

5' Primer

ACC GTC ACC ATG GGG GGG GGG TAA ATG ACC AGG GGG GTC AAC GAG GTC GGG AAG
AAG AAG AAG GGG GGT GAC GGA GAG GGG GAG ACC AAG AGC

3' Primer

GGG ATT GAG GAG TAG GGG GAG GGG GAG TAG

The new RIP gene derivative is called RDT and encodes a protein of predicted a 28,233 Daltons and pI ~9.5. The RDT gene encodes a protein with a truncated leader, deleted linker and truncated carboxy terminus.

The DNA sequence for RDT is shown in Table 8.

Table 8: Nucleotide sequence and deduced amino acid sequence of the maize RIP derivative RDT.

The RDT gene, expressed in *E.coli* using the pGEMEX system described above, was purified from bacterial lysates to apparent homogeneity. RDT protein appears to be a more potent inhibitor of protein synthesis than R30-DL. Using the reticulocyte lysate protein synthesis assay, purified RDT has a IC_{50} value of 1 ng/ml.

25

Table 10

Predicted nucleotide sequence and deduced amino acid
sequence of the maize RIP derivative RDT-NP

Table 10: Predicted nucleotide sequence and deduced amino acid sequence of the maize RIP derivative RDT-10

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
7

The RDT-NP polypeptide had a predicted molecular weight of 28,446 Daltons and pI of 9.5. Crude
55 lysates of *E.coli* expressing RDT-NP from a pGEMEX vector are potent inhibitors of eukaryotic protein
synthesis.

Example 10:

To create an RIP molecule which would bind to immunoglobulin IgG, a single Antibody Binding Region (ABR) domain from the *Staphylococcus aureus* antibody binding Protein A was subcloned from the plasmid pRIT5 (Pharmacia LKB Biotechnology) using PCR techniques. The antibody binding domain of protein A (ABR-A) was PCR engineered to have a *Bam* HI site at its 5' end and a *Bgl* II site at its 3' end. This allowed
 5 insertion of the ABR-A domain into the RDT *Bam* HI site while retaining the unique *Bam* HI site. The sequence of RDT-A is shown in Table 11.

10

15

20

25

30

35

40

45

50

55

Table 11

Predicted nucleotide sequence and deduced amino acid sequence of RDT-A.

		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	700	701	702	703	704	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000	1001	1002	1003	1004	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017	1018	1019	1020	1021	1022	1023	1024	1025	1026	1027	1028	1029	1030	1031	1032	1033	1034	1035	1036	1037	1038	1039	1040	1041	1042	1043	1044	1045	1046	1047	1048	1049	1050	1051	1052	1053	1054	1055	1056	1057	1058	1059	1060	1061	1062	1063	1064	1065	1066	1067	1068	1069	1070	1071	1072	1073	1074	1075	1076	1077	1078	1079	1080	1081	1082	1083	1084	1085	1086	1087	1088	1089	1090	1091	1092	1093	1094	1095	1096	1097	1098	1099	1100	1101	1102	1103	1104	1105	1106	1107	1108	1109	1110	1111	1112	1113	1114	1115	1116	1117	1118	1119	1120	1121	1122	1123	1124	1125	1126	1127	1128	1129	1130	1131	1132	1133	1134	1135	1136	1137	1138	1139	1140	1141	1142	1143	1144	1145	1146	1147	1148	1149	1150	1151	1152	1153	1154	1155	1156	1157	1158	1159	1160	1161	1162	1163	1164	1165	1166	1167	1168	1169	1170	1171	1172	1173	1174	1175	1176	1177	1178	1179	1180	1181	1182	1183	1184	1185	1186	1187	1188	1189	1190	1191	1192	1193	1194	1195	1196	1197	1198	1199	1200	1201	1202	1203	1204	1205	1206	1207	1208	1209	1210	1211	1212	1213	1214	1215	1216	1217	1218	1219	1220	1221	1222	1223	1224	1225	1226	1227	1228	1229	1230	1231	1232	1233	1234	1235	1236	1237	1238	1239	1240	1241	1242	1243	1244	1245	1246	1247	1248	1249	1250	1251	1252	1253	1254	1255	1256	1257	1258	1259	1260	1261	1262	1263	1264	1265	1266	1267	1268	1269	1270	1271	1272	1273	1274	1275	1276	1277	1278	1279	1280	1281	1282	1283	1284	1285	1286	1287	1288	1289	1290	1291	1292	1293	1294	1295	1296	1297	1298	1299	1300	1301	1302	1303	1304	1305	1306	1307	1308	1309	1310	1311	1312	1313	1314	1315	1316	1317	1318	1319	1320	1321	1322	1323	1324	1325	1326	1327	1328	1329	1330	1331	1332	1333	1334	1335	1336	1337	1338	1339	1340	1341	1342	1343	1344	1345	1346	1347	1348	1349	1350	1351	1352	1353	1354	1355	1356	1357	1358	1359	1360	1361	1362	1363	1364	1365	1366	1367	1368	1369	1370	1371	1372	1373	1374	1375	1376	1377	1378	1379	1380	1381	1382	1383	1384	1385	1386	1387	1388	1389	1390	1391	1392	1393	1394	1395	1396	1397	1398	1399	1400	1401	1402	1403	1404	1405	1406	1407	1408	1409	1410	1411	1412	1413	1414	1415	1416	1417	1418	1419	1420	1421	1422	1423	1424	1425	1426	1427	1428	1429	1430	1431	1432	1433	1434	1435	1436	1437	1438	1439	1440	1441	1442	1443	1444	1445	1446	1447	1448	1449	1450	1451	1452	1453	1454	1455	1456	1457	1458	1459	1460	1461	1462	1463	1464	1465	1466	1467	1468	1469	1470	1471	1472	1473	1474	1475	1476	1477	1478	1479	1480	
--	--	---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	--

manufacturer's instructions. Binding was best at pH 7.0. When washed at pH 5.0 the chimeric protein was released in small but detectable quantities from the resin. RDT alone does not bind to the gel.

Example 11:

To increase the binding ability of the RDT-A to IgG antibodies the Antibody Binding Domain from Streptococcal Group G protein G (ABR-G) was synthesized using oligonucleotides. The sequence synthesized was that of the naturally occurring sequence described by Guss *et al.* ((1986), EMBO Journal, 5:1567-1575). The only change was the addition of *Bam* HI and *Bgl* II sites at the 5' and 3' ends respectively of the synthetic DNA.

The ABR-G fragment was inserted into the *Bam* HI site of RDT-A. Two classes of clones have been studied. RDT-G-A contains a single ABR-G domain inserted in the correct orientation between the 3' end of RDT and the 5' end of ABR-A. A second class contains two properly oriented ABR-G domains. The predicted DNA sequences for the genes are shown in Tables 12 and 13.

Table 12

Predicted nucleotide and deduced amino acid sequence for RDT-G-A.

25	1	TCGCTGTAGATCGGGCCTAATTAATTAAGCTTAAAGGAGGAAAAAATT	ATC AAA
			Met Lys>
	27	ACA ATA GTG CCA AAG TTC ACT GAA ATC TTC CGC GTG CAG CAC GCG	
	31	Arg Ile Val Pro Lys Phe Thr Glu Ile Phe Pro Val Glu Asp Ala>	
	32	AAC TAC CCT TAC AGC GGC TTC ATC GCG TCG GTC CCG AAA GAC GTG	
	38	Asn Tyr Pro Tyr Ser Ala Phe Ile Ala Ser Val Arg Lys Asp Val>	
30	47	ATC AAA CAC TGC ACC GAC CAT AAA GCG ATC TTC CAG CCC GTG CTG	
	53	Ile Lys His Cys Thr Asp His Lys Gly Ile Phe Gln Pro Val Leu>	
	192	CCA CGC CAG AAG AAG GTC CGC GAG CTA TCG TTC TAC ACA GAG CTC	
	198	Pro Pro Glu Lys Lys Val Pro Glu Leu Trp Phe Tyr Thr Glu Leu>	
35	237	AAA ACT AGG ACC AGC TCC ATC ACG CTC GGC ATA CCG ATG CAC AAC	
	243	Lys Thr Arg Thr Ser Ser Ile Thr Leu Ala Ile Arg Met Asp Asn>	
	282	CTG TAC CTC GTG GGC TTC AGG ACC CGC GGC GGC GTG TCG TCG CAG	
	288	Leu Tyr Leu Val Gly Phe Arg Thr Pro Gly Gly Val Trp Trp Glu>	
	327	TTC GGC AAG CAC GGC GAC ACC CAC CTC CTC GGC GAC AAC CCC AGG	
	333	Phe Gly Lys Asp Gly Asp Thr His Leu Leu Gly Asp Asn Pro Arg>	
40	372	TGG CTC GGC TTC GGC GGC AGG TAC CAG GAC CTC ATC GGC AAC AAG	
	378	Trp Leu Gly Phe Gly Gly Arg Tyr Gln Asp Leu Ile Gly Asn Lys>	
	417	GGT CTG CAG ACC GTC ACC ATG GGC CGC GGC GAA ATG ACC AGC GGC	
	423	Gly Leu Glu Thr Val Thr Met Gly Arg Ala Glu Met Thr Arg Ala>	
45	462	CTC AAC CAC CTC GCG AAG AAG AAG AAG GCG GGT CAC CCA CAG GCG	
	468	Val Asn Asp Leu Ala Lys Lys Lys Lys Ala Ala Asp Pro Gln Ala>	
	507	GAC AGC CAG ACC AAG GTC GTC AAG GTC GTC GTC ATG GTC TCG CAG	
	513	Asp Thr Lys Ser Lys Leu Val Lys Leu Val Val Met Val Cys Glu>	
	552	TGG GTC GCG TTC AAC ACC GTC TCG GCG ACC GTC CAC GCG GCG TTC	
	558	Gly Leu Arg Phe Asn Thr Val Ser Arg Thr Val Asp Ala Gly Phe>	
50	597	GAC AGC CAG CAC GCG GTC ACC TTC ACC GTC ACC CAG GCG AAG CAG	
	603	Asn Ser Glu His Gly Val Thr Leu Thr Val Thr Glu Lys Glu>	
	642	TTC CAG CAG TCG CAC ACG ATC TTC CAG GCG GCG TTC CAG TCG GGT	
	648	Val Glu Lys Trp Asp Arg Ile Ser Lys Ala Ala Phe Glu Trp Ala>	
55	687	GAC CAG GCG ACC GGT GTC ATC GCG CAC ATG CAG AAG GTC GCG ATC	
	693	Asp Glu Trp Thr Ala Val Val Arg Asp Met Glu Lys Leu Gly His>	
	732	AAG GAT AA AAC GAA GCA GCG AGG ATC GTT GCG CTC GTT AAG AAT	
	738	Lys Asp Lys Asn Glu Ala Ala Arg Ile Val Ala Leu Val Lys Asn>	

Table 12 (cont.)

5

10

15

20

25

30

35

40

45

50

55

```

777   CAA ACT ACT GGC GGT GCC GGT ACT GGT CGA TCC AAA CCA GAA GTC
243   Gln Thr Thr Ala Ala Ala Ala Thr Ala Gly Ser Lys Pro Glu Val>

922   ATC GAT GCG TGT GAA TTA ACA CCA GCG GTG ACA ACT TAC AAA GTT
258   Ile Asp Ala Ser Glu Leu Thr Pro Ala Val Thr Thr Tyr Lys Leu>

967   GTT ATT AAT GGT AAA ACA TTG AAA GCG GAA ACA ACT ACT GAA GGT
273   Val Ile Asn Gly Lys Thr Leu Lys Gly Glu Thr Thr Thr Glu Ala>

112   ATT GAT GGT GGT ACT GCA GAA AAA GTG TTT AAA CAA TAC GGT AAC
128   Val Asp Ala Ala Thr Ala Ile Lys Val Phe Lys Gln Tyr Ala Asp>

157   GAC AAC GGT GGT GAC GGT GAA TCC ACT TAC GAC GAT GCG ACT AAC
173   Asp Asn Gly Val Asp Gly Glu TCC Thr Tyr Asp Asp Ala Thr Lys>

192   TCG GTT TCA GTT TGT GAA AAA GCG GAA TTG ATG GAT GCG TGT GAA
208   Thr Phe Thr Val Thr Glu Lys Pro Glu Val Thr Thr Asp Ala Ser Val>

227   TTA ACA CCA GCG GTG ACA AGA TCC GGT GAT AAC AAT TTT AAC AAA
243   Leu Thr Pro Ala Val Thr Arg Ser Ala Asp Asn Asn Phe Asn Lys>

262   GAA GAA GAA AAT GGT TTT TAT GAA ATG TTT AAT ATG GGT AAC TTA
278   Glu Gln Gln Asn Ala Phe Tyr Glu Glu Leu Asn Met Pro Asn Leu>

307   TAC GAA GAA GAA GCG AAT TGT TTT ATG GAA AGG TTA AAA GAT GTC
323   Val Glu Glu Gln Arg Asn Ile Phe Ile Gln Ser Leu Lys Asp Asp>

342   TCA AGC GAA AGT GGT AAC GTA TTT TCA GAA GGT AAA AAG TTA AAT
358   Pro Ser Gln Ser Ala Asn Leu Leu Ser Glu Ala Lys Lys Leu Asn>

1227  GAA TGT CAA GCA CCG AAA GAT CGA TCC GCC TGATCAATGCACGACACA
393  Glu Ser Gln Ala Pro Lys Asp Arg Ser Ala End<

1276  TGATGATCTGCTGCTGCACTTAATTACTATGTTGATATACAAATAAATACACCGCGCT
1335  ACCCGGTGTCCTTATATGCTGTAAATGTACCGCAATAATTTAACTAGTTTCTGCT
1394  TCCGAATTCAGTGGCGGGCATGCTATATA

```

Table 13

Predicted nucleotide and deduced amino acid sequence for
RDT-G-G-A.

	TAGATCGCGGCTAATTAAATTAGCTTAAAGGAGGAAAAAAAT. ATG AAA Met Lys>
10	57 3	AGA ATA GTG CCA AAG TTC ACT GAA ATC TTC CCC GTG GAG GAC GCG Arg Ile Val Pro Lys Phe Thr Glu Ile Phe Pro Val Glu Asp Ala>
	102 18	AAC TAC GGT TAC AGC GGC TTC ATC GCG TCG GTC CCG AAA GAC GTG Asn Tyr Pro Tyr Ser Ala Phe Ile Ala Ser Val Arg Lys Asp Val>
15	147 33	ATC AAA CAC TGC ACC GAC CAT AAA GCG ATC TTC CAG CCC GTG GTG Ile Lys His Cys Thr Asp His Lys Gly Ile Phe Gln Pro Val Leu>
	192 48	CCA CCG GAG AAG AAG GTC CCG GAG CTA TCG TTC TAC ACA GAG CTC Pro Pro Glu Lys Lys Val Pro Glu Leu Trp Phe Tyr Thr Glu Leu>
	237 63	AAA ACT ACC ACC ACC TCC ATC ACC CTC GCG ATA CCG ATG GAC AAC Lys Thr Arg Thr Ser Ser Ile Thr Leu Ala Ile Arg Met Asp Asn>
20	282 78	CTG TAC CTC GTG GCG TTC AGG ACC CCG GCG GCG GTG TCG TCG GAG Leu Tyr Leu Val Gly Phe Arg Thr Pro Gly Gly Val Trp Trp Glu>
	327 93	TTC GCG AAG GAC GCG GAC ACC GAC CTC CTC GCG GAC AAC CCG AGG Phe Gly Lys Asp Gly Asp Thr His Leu Leu Gly Asp Asn Pro Arg>
25	372 108	TGG CTC GCG TTC GCG GCG AGG TAC CAG GAC CTC ATC GCG AAC AAG Trp Leu Gly Phe Gly Gly Arg Tyr Gln Asp Leu Ile Gly Asn Lys>
	417 123	GCT CTC GAG ACC GTC ACC ATG GCG CCG GCG GAA ATG ACC AGC GCG Gly Leu Glu Thr Val Thr Met Gly Arg Ala Glu Met Thr Arg Ala>
	462 138	GTC AAC GAC CTC GCG AAG AAG AAG AAG GCG GCT GAC CCA CAG GCG Val Asn Asp Leu Ala Lys Lys Lys Lys Ala Ala Asp Pro Gln Ala>
30	507 153	GAC ACC AAG ACC AAG CTC GTC AAG CTC GTC GTC ATG GTC TCC GAG Asp Thr Lys Ser Lys Leu Val Lys Leu Val Val Met Val Cys Glu>
	552 168	CGG CTC GCG TTC AAC ACC GTC TCC GCG ACC GTC GAC GCG GCG TTC Gly Leu Arg Phe Asn Thr Val Ser Arg Thr Val Asp Ala Gly Phe>
35	597 183	GAC AGC GAG CAC GCG GTC ACC TTC ACC GTC ACC GAG GCG AAG CAG Gln Ser Gln His Gly Val Thr Leu Thr Val Thr Gln Gly Lys Gln>
	642 198	CTG GAG AAG TCG GAC AGC ATG TCG AAG GCG GCG TTC GAG TCG GCT Leu Glu Lys Thr Asp Arg Ile Ser Lys Ala Ala Phe Gln Thr Ala>
	687 213	AAG GAG GCG ACC GGT GTG ATG GCG GAC ATG CAG AAG GTC GCG ATG Asp His Phe Thr Ala Val Ile Pro Asp Met Gln Lys Leu Gly Ile>
40	732 219	AAG GAT AAG AAG GAA GCA GCG AGG ATG GTT TCG CTC GTT GAG AAT Lys Thr Lys Asp Ile Thr Ala Val Thr Thr Thr Thr Thr Thr Thr>
	777 243	GAA ACT ACT GCG GGT GCG GGT ACT GGT GCA TCG AAA CCA GAA GTG Glu Thr Thr Ala Ala Ala Ala Thr Ala Gly Ser Lys Pro Glu Val>
	822 258	TTC GAT GCG TGT GAA TTA ACA TCA GCG GTG ACA ACT TAC GAA CTC Leu Asp Ala Ser Glu Leu Thr Pro Ala Val Thr Thr Tyr Lys Leu>
45	867 273	TTC ATT GAT GGT AAA ACA TTC AAA GCG GAA ACA ACT ACT GAA GGT Val Ile Asn Gly Lys Thr Leu Lys Gly Glu Thr Thr Thr Glu Ala>
	912 288	TTC GAG GGT GGT TGT GCA GAA AAA GTC TTC AAA CAA TAC GGT AAC Val Asp Ala Ala Thr Ala Glu Lys Val Phe Lys Gln Tyr Ala Asn>
50	957 303	TAC AAG GGT GTT TGT GGT GAA TCG ACT TAC GAC GAT GCG ACT AAG Tyr Asn Gly Val Thr Gly Glu Thr Thr Tyr Asp Asp Ala Thr Lys>
	1002 318	TTC TTT TCA GTT TGT GAA AAA GCA GAA GTG ATG GAT GCG TGT GAA Phe Phe Val Thr Thr Glu Lys Phe Thr Thr Thr Thr Thr Thr Thr>

Table 13 (cont.)

5

10	1047 333	TTA ACA CCA GCC GTG ACA ACA TCC AAA CCA GAA GTG ATC GAT GCG Leu Thr Pro Ala Val Thr Arg Ser Lys Pro Glu Val Ile Asp Ala>
	1092 348	TCT GAA TTA ACA CCA GCC GTG ACA ACT TAC AAA CTT GTT ATT AAT Ser Glu Leu Thr Pro Ala Val Thr Thr Tyr Lys Leu Val Ile Asn>
15	1137 363	GCT AAA ACA TTG AAA GCC GAA ACA ACT ACT GAA GCT GTT GAT GCT Gly Lys Thr Leu Lys Gly Glu Thr Thr Thr Glu Ala Val Asp Ala>
	1182 378	GCT ACT GCA GAA AAA GTC TTC AAA GAA TAC GCT AAC GAC AAC GGT Ala Thr Ala Glu Lys Val Phe Lys Gln Tyr Ala Asn Asp Asn Gly>
	1227 393	GTT GAC GGT GAA TGG ACT TAC GAC GAT GCG ACT AAG ACC TTT ACA Val Asp Gly Glu Trp Thr Tyr Asp Asp Ala Thr Lys Thr Phe Thr>
20	1272 408	ATT ACT GAA AAA CCA GAA GTG ATC GAT GCG TCT GAA TTA ACA CCA Val Thr Glu Lys Pro Glu Val Ile Asp Ala Ser Glu Leu Thr Phe>
	1317 423	TCC GTG ACA AGA TCC GCT GAT AAC AAT TTC AAC AAA GAA GAA GAA Lys Val Thr Trp Ser Ala Phe Asn Asn Phe Asn Lys Glu Ser Glu>
25	1362 438	AAT GCT TTC TAC GAA ATC TTC AAT ATC GCT AAC TTA AAC GAA GAA Asn Ala Phe Thr Glu Ile Leu Asn Met Phe Asn Leu Asn Glu Glu>
	1407 453	GAA GCG AAT TCT TTC ATC TTA AGC TTA AAA GAT GAC CCA AGC GAA Glu Arg Asn Gly Phe Ile Leu Ser Leu Lys Asp Asp Pro Ser Glu>
	1452 468	AAT GCT AAC TTA TTC TCA GAA GCT AAA AAG TTA AAT GAA TCT GAA Ser Ala Asn Leu Leu Ser Glu Ala Lys Lys Leu Asn Glu Ser Glu>
30	1497 483	TCA GCG AAA GAT CCA TCC GCG TCATCAATGCAACGACACATGATGATGCT Ala Pro Lys Asp Arg Ser Ala End<
	1549	GCTGCACCTTAATTACTATGTTGGTATACAAATAAATACACCCGGCGTACCGCGGTGTTCC
	1608	TCATATGCTGTAAATGTAGCCAGTAAATTTTAACTACTTTCTGTCGCGGAATTCAC
35	1667	TCCCGGCATGCTATATA

When these genes were expressed in *E.coli* using the pGEMEX system the expected chimeric proteins were produced. The RDT-G-A produced a protein of predicted molecular weight 44,576 Daltons (pI 7.2). RDT-G-G-A produced a slightly larger polypeptide predicted to be 53,955 Daltons with a predicted pI of 5.4.

Crude bacterial lysates of cells expressing RDT-G-A or RDT-G-G-A were potent inhibitors of eukaryotic protein synthesis in the rabbit reticulocyte assay described in Example 1. Papain treatment of the lysates further increases activity. Analysis of the papain treated lysates indicates that the intact RDT domain is released from the ABR domains.

Both RDT-G-A and RDT-G-G-A bind tightly to IgG Sepharose (Pharmacia LKB Biotechnology). Binding is stable at pH 5.0 Elution was accomplished with 0.5 M ammonium acetate pH 3.5 or by boiling the resin in SDS.

Example 12:

Seeds from the following species of *Panicoideae* were ground to a fine consistency in a mortar and pestle (after removal of the glume if necessary): *Zea mays mays*, *Z.m. mexicana*, *Z.m. parviglumis*, *Z. luxurians*, *Z. mexicana*, *Z. mexicana*, *Tripsacum dactyloides*, *Coix lachryma-jobi*, *Sorghum bicolor*.

Soluble proteins were extracted from mature dry seed by the following techniques. The proteins were extracted for 2 hours with 50 mM sodium phosphate buffer, pH 7.5 containing 25 µg/ml leupeptin, 25 µg/ml antipain, 2 mM EDTA and 4 mM phenylmethane sulfonyl fluoride. Three milliliter extraction buffer per gram seed tissue was used. After centrifugation to remove insoluble material, an aliquot of the extract was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis using 17-27% gradient gels, then electroblotted onto PVDF paper (Millipore). The blot was probed using rabbit antisera against maize RIP α

and β fragments (1:2000 dilution each) as primary antibody and goat anti-rabbit IgG antibody as secondary antibody, then developed with NBT/BCIP.

Except the *Coix* extract, all the extracts tested showed cross-reactivity with the maize RIP antisera. A prominent band at ~34 kD was observed corresponding to proRIP, and bands at ~16.5 and 8.5 kD were also observed, corresponding to α and β fragments respectively. This indicates that RIP forms equivalent to maize proRIP and the activated $\alpha\beta$ form are present in many members of the subfamily Panicoideae.

Example 13:

Total DNA from the following species was isolated according to the procedures described by Saghai-Maroo et al., *PNAS*, 81:8014-8018, 1984. The following species of *Panicoideae* were included: 3 accessions of *Zea mays* ssp.; *parviglumis*; *Zea luxurians*; *Zea mays* ssp. *mexicana*; *Coix lachryma-jobi*; *Sorghum bicolor*, and *Zea mays* ssp. *mays* var. B73.

Generally, about 8 μ g of the extracted DNA from each sample was digested to completion with 20 units of *Hind* III, *Eco* RI and *Sst* I in 20 microliters of a reaction mixture containing the appropriate reaction buffer at 37°C for 2 hours.

Next, the total extracted DNA from each sample was subjected to the Southern hybridization technique (see Southern (1975), *J.Mol.Biol.*, 98:503-517). The DNA fragments were fractionated on the basis of their size by means of electrophoresis on a 0.8% agarose gel. The double-stranded DNA fragments were modified into single-stranded DNA fragments in an alkali solution; and then a nylon filter was placed into close contact with the gel to transfer the modified DNA segments onto the filter in the presence of a high salt concentration solution.

Hybridization was carried out using, as the probe, the cDNA clone of the RIP gene (the probe fragment is provided from position 2 to 1075 in Table 1). The probe was radiolabeled with 32 P and the signals in Southern transfers were visualized by autoradiography.

The Southern blots were hybridized with the cDNA clone of the RIP gene. A single fragment with strong homology to the clone was observed for each enzyme/species combination except the *Coix* accession. The inbred line of maize has a single major band with two minor bands. The other species which, with the exception of *Sorghum*, are not inbred showed between 2 and 5 minor bands. The *Coix* had either 4 or 5 such bands depending on the enzyme used.

Although the invention has been described in considerable detail, with reference to certain preferred embodiments thereof, it will be understood that variations and modifications can be affected within the spirit and scope of the invention as described above and as defined in the appended claims.

Claims

1. A substantially pure protein, termed a proRIP, wherein the protein is incapable of substantially inactivating eukaryotic ribosomes, but which can be converted into a protein, termed an RIP, that is capable of substantially inactivating eukaryotic ribosomes, said proRIP having a removable, internal peptide linker sequence.
2. The substantially pure protein of Claim 1, wherein the protein is derived from a *Panicoideae*.
3. The substantially pure protein of Claim 1, wherein the proRIP has a removable, internal peptide linker selectively inserted in the amino acid sequence of a protein capable of substantially inactivating eukaryotic ribosomes, termed an $\alpha\beta$ RIP derived from the group consisting of *Panicoideae* RIP, barley RIP, ricin A-chain RIP, saporin RIP, abrin A-chain RIP, SLT-1 RIP, α -trichosanthin RIP, Luffin-A RIP, and Mirabilis antiviral protein RIP.
4. The substantially pure protein of Claim 3, wherein the internal peptide linker has a sequence effectively homologous to the following amino acid sequence:

MATLEEEEVKMQMQMPEAADLAAAA.

5. The substantially pure protein of Claim 3, wherein the maize proRIP, has an amino acid sequence effectively homologous to the following sequence:

KRIVPKFTEIFPVEDANYPYSAFIASVRKDVIKHCTDHKGIFQPVLPPEKKVPELW
 FYTELKTRTSSITLAIRMDNLYLVGFRTPGGVWWEFGKD
 5 GDTHLLGDNPRWLGFGGRYQDLIGNKGLETVTMGRAEMTR
 AVNDLAKKKKMATLEEEVKMOMOMPEAADLAAAAADPQADTKSKLVK
 LVVMVCEGLRFNTVSRITVDAGFNSQHGVTTLTVTQGKQVQKWDRI
 10 KAAFEWADHPTAVIPDMQKLGKDKNEAARIVALVKNQTTAAAATAAS
 ADNDDEA.

- 15 6. A substantially pure protein, termed an RIP, having α and β fragments and being capable of substantially inactivating eukaryotic ribosomes derived from a *Panicoideae*.
7. The substantially pure protein of Claim 6, wherein the α fragment has an amino acid sequence effectively homologous to the following sequence:

KRIVPKFTEIFPVEDANYPYSAFIASVRKDVIKHCTDHKGIFQPVLPPEKKVPELW
 FYTELKTRTSSITLAIRMDNLYLVGFRTPGGVWWEFGKD
 20 GDTHLLGDNPRWLGFGGRYQDLIGNKGLETVTMGRAEMTR
 25 AVNDLAKKKK

and the β fragment has an amino acid sequence effectively homologous to the following sequence:

DPQADTKSKLVKLVVMVCEGLRFNTVSRITVDAGFNSQHGVTTLTVTQGKQVQKWDRI
 SKAAFEWADHPTAVIPDMQKLGKDKNEAARIVAL
 30 VKNQTTAAAATAASADNDDEA.

- 35 8. A substantially pure protein having α and β fragments and being capable of substantially inactivating eukaryotic ribosomes, termed an $\alpha\beta$ RIP, wherein the $\alpha\beta$ RIP is derived from the group consisting of *Panicoideae* RIP, barley RIP, ricin A-chain RIP, saporin RIP, abrin A-chain RIP, SLT-1 RIP, and α -trichosanthin RIP, Luffin-A RIP, and Mirabilis antiviral protein RIP.
9. A fusion protein capable of substantially inactivating eukaryotic ribosomes, said protein having an amino acid sequence effectively homologous to the following sequence:

KRIVPKFTEIFPVEDANYPYSAFIASVRKDVIKHCTDHKGIFQPVLPPEKKVPELW
 FYTELKTRTSSITLAIRMDNLYLVGFRTPGGVWWEFGKD
 45 GDTHLLGDNPRWLGFGGRYQDLIGNKGLETVTMGRAEMTR
 50 AVNDLAKKKKDPQADTKSKLVKLVVMVCEGLRFNTVSRITVDAGFNSQHG
 VTLTVTQGKQVQKWDRIKAAFEWADHPTAVIPDMQKLGKDKN
 55 EAARIVALVKNQTTAAAATAASADNDDEA.

10. A conjugate comprising a targeting vehicle and a protein, termed a proRIP, wherein the proRIP has a removable, internal peptide linker sequence and is incapable of substantially inactivating eukaryotic

ribosomes, but which upon removal of the linker can be converted into a protein having α and β fragments, termed an $\alpha\beta$ RIP, that is capable of substantially inactivating eukaryotic ribosomes.

11. The conjugate of Claim 10 wherein the protein is derived from the group consisting of a *Panicoideae* RIP, barley RIP, ricin A-chain RIP, saporin RIP, abrin A-chain RIP, SLT-1 RIP, and α -trichosanthin RIP, Luffin-A RIP, and Mirabilis antiviral protein RIP.
12. A conjugate comprising a targeting vehicle and a protein, termed an $\alpha\beta$ RIP, that is capable of substantially inactivating eukaryotic ribosomes and that contains α and β fragments.
13. A conjugate comprising a targeting vehicle and a protein derived from maize, termed a proRIP, wherein the proRIP has a removable, internal peptide linker sequence and is incapable of substantially inactivating eukaryotic ribosomes, but which upon removal of the linker can be converted into a protein having α and β fragments, termed an RIP, that is capable of substantially inactivating eukaryotic ribosomes, said α fragment having an amino acid sequence effectively homologous to the following sequence:

KRIVPKFTEIFPVEDANYPYSAFIASVRKDVIKHCTDHKGIFQPVLPPEKKVPELW
 FYTELKTRTSSITLAIRMDNLYLVGFRTPGGVWWEFGKD
 GDTHLLGDNPRWLGFGGRYQDLIGNKGLETVTMGRAEMTR
 AVNDLAKKKK

and the β fragment having an amino acid sequence effectively homologous to the following sequence:

DPQADTKSKLVKLVVMVCEGLRFNTVSRTVDAGFNSQHGVTLTVTQGKQVQKWDRISKAAFEWADHPTAVIPDMQKLGKDKNEAARIVAL
 VKNQTTAAAATAASADNDDEA.

14. A conjugate comprising a targeting vehicle and a fusion protein capable of substantially inactivating eukaryotic ribosomes, said protein having an amino acid sequence effectively homologous to the following sequence:

KRIVPKFTEIFPVEDANYPYSAFIASVRKDVIKHCTDHKGIFQPVLPPEKKVPELW
 FYTELKTRTSSITLAIRMDNLYLVGFRTPGGVWWEFGKD
 GDTHLLGDNPRWLGFGGRYQDLIGNKGLETVTMGRAEMTR
 AVNDLAKKKKDPQADTKSKLVKLVVMVCEGLRFNTVSRTVDAGFNSQHG

VTLTQGKQVQKWDRISKAAFEWADHPTAVIPDMQKLGKDKNEAARIVALVKNQTTAAAATAASADNDDEA.

15. The conjugate of any one of Claims 10 to 15, wherein the targeting vehicle is selected from the group consisting of hormones, antibodies, antibody binding proteins, growth factors and lectins, or fragments thereof.
16. A method for converting a proRIP into an RIP, said method comprising the following steps:
 - a) providing a homogeneous protein derived from the group consisting of consisting of a *Panicoideae* RIP, barley RIP, ricin A-chain RIP, saporin RIP, abrin A-chain RIP, SLT-1 RIP, and α -trichosanthin RIP, Luffin-A RIP, and Mirabilis antiviral protein RIP, termed a proRIP, wherein the

proRIP has a removable, internal peptide linker sequence and is incapable of substantially inactivating eukaryotic ribosomes, but which upon removal of the linker can be converted into a protein having α and β fragments, termed an RIP, that is capable of substantially inactivating eukaryotic ribosomes; and

b) contacting the proRIP with a cleaving agent capable of deleting the linker to form a protein having α and β fragments, termed an RIP, that is capable of substantially inactivating eukaryotic ribosomes.

17. A DNA isolate capable of encoding a protein, termed a proRIP, wherein the proRIP has a removable, internal peptide linker sequence and is incapable of substantially inactivating eukaryotic ribosomes, but which upon removal of the linker can be converted into a protein having α and β fragments, termed an RIP, that is capable of substantially inactivating eukaryotic ribosomes.

18. The DNA isolate of Claim 17, wherein the DNA isolate encodes a protein derived from the group consisting of consisting of *Panicoideae* RIP, barley RIP, ricin A-chain RIP, saporin RIP, abrin A-chain RIP, SLT-1 RIP, and α -trichosanthin RIP, Luffin-A RIP, and Mirabilis antiviral protein RIP.

19. The DNA isolate of Claim 17, wherein the DNA isolate encodes the maize proRIP of Claim 5.

20. A DNA isolate encoding a fused protein capable of substantially inactivating eukaryotic ribosomes, said protein having an amino acid sequence effectively homologous to the following sequence:

KRIVPKFTEIFPVEDANYPYSAFIASVRKDVIKHCTDHKGIFQPVLPPEKKVPELW
FYTELKTRTSSITLAIRMDNLYLVGFRTPGGVWWEFGKD
GDTHLLGDNPRWLGFGGRYQDLIGNKGLETVTMGRAEMTR
AVNDLAKKKKDPQADTKSKLVKLVVMVCEGLRFNTVSRTVDAGFNSQHG
VTLTVTQGKQVQKWDRISKA AFEWADHPTAVIPDMQKLGKDKN
EAARIVALVKNQTTAAAATAASADNDDDEA.

21. A DNA isolate encoding an RIP having at least one sites engineered therein, whereby the DNA isolate may be cleaved by restriction enzymes to permit insertion of a DNA sequence encoding a linker.

22. A biologically functional expression vehicle containing a DNA isolate of any one of Claims 17 to 21.

23. A host cell transformed with a biologically functional expression vehicle of Claim 22.

24. The transformed host cell of Claim 23, wherein the host cell is a eukaryotic cell.

25. The host cell of Claim 24, wherein the host cell is maize.

26. A method of creating a protein incapable of substantially inactivating eukaryotic ribosomes, termed a proRIP, said method comprising the steps of

- (a) providing a first DNA sequence encoding an RIP having at least one sites engineered therein,
- (b) cleaving the first DNA sequence with a restriction enzyme to form first DNA subsequences,
- (c) proving a second DNA isolate encoding a polypeptide of desired length and amino acid residues and having ends ligatable with the cleaved ends of the first DNA subsequences,
- (d) ligating the first DNA subsequences and the and second DNA to form a third DNA sequence capable of expressing a proRIP,
- (e) expressing the proRIP.

FIG. 1 *Processing of maize proRIP to active form*





FIG. 2 Inhibition of protein synthesis in a rabbit reticulocyte lysate by purified maize RIP.





European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 91201436.2

DOCUMENTS CONSIDERED TO BE RELEVANT

DOCUMENTS CONSIDERED TO BE RELEVANT			EP 91201436.2
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
Y	GB - A - 2 216 891 (FARMITALIA CARLO ERBA S.r.I.) * Example; claims *	1,10, 15,17, 22,23	C 07 K 15/10 C 12 N 15/29 C 12 N 5/10
D,Y	EUROPEAN JOURNAL OF BIOCHE- MISTRY, vol. 148, 1985, New York, Berlin F. I. LAMB et al. " Nucleotide sequence of cloned cDNA coding for preproricin" pages 265-270 * Discussion *	1,3, 16,17	
D,A	CANCER SURVEYS, vol. 1, no. 3, 1982, Oxford, England L. BARBIERI and F. STIRPE "Ribosome-inactivating pro- teins from plants: Properties and possible uses" pages 489-520 * Page 511-512 *	1,22- 26	
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
			C 07 K C 12 N A 61 K
The present search report has been drawn up for all claims			
Place of search VIENNA	Date of completion of the search 23-08-1991	Examiner AUGUSTIN	
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			